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ABSTRACT 
 
Esophageal cancer is the eighth most common invasive cancer in the world, a cancer 
with an increasing incidence and male predominance, and there is a great need for 
potential dietary prevention. The overall aim of this thesis was to evaluate whether the 
dietary phytoestrogens lignans might play a protective role in the etiology of 
esophageal cancer, including gastroesophageal junctional adenocarcinoma.  
 
In Paper I, we examined the association between intake of dietary lignans based on a 
63-item food frequency questionnaire (FFQ) and risk of esophageal cancer in a 
Swedish nationwide population-based case-control study conducted in 1995-1997. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Participants in 
the highest quartile of lignan intake compared with the lowest quartile showed a 
decreased risk of esophageal adenocarcinoma (OR=0.65; 95% CI: 0.38-1.12) and 
gastroesophageal junctional adenocarcinoma (OR=0.37; 95% CI: 0.23-0.58), while no 
clear associations were found for esophageal squamous-cell carcinoma.   
 
In Paper II, we validated the use of two FFQs (the 67-item FFQ-87 and the 93-item 
FFQ-97) for the assessment of dietary lignans compared to the serum biomarker 
enterolactone, the main metabolite of dietary lignans in the human body. Based on the 
FFQ-97, the correlation between lignan intake and serum enterolactone was significant, 
but the value of the correlation coefficient was small (r=0.22, p=0.01). No significant 
correlation was observed for the FFQ-87. 
 
In Paper III, we further evaluated the possible association between lignan intake based 
on the FFQ-97 and risk of esophageal and gastric adenocarcinoma using a prospective 
study design. Among 81,670 participants who were followed up during 1998-2009, 
hazard ratios (HRs) and 95% CIs were calculated. No statistically significantly 
decreased risk was found. Compared with the lowest quartile of lignan intake, the 
adjusted HRs of the highest quartile were 0.96 (95% CI: 0.46-2.00) for esophageal and 
gastroesophageal junctional adenocarcinoma, and 0.89 (95% CI: 0.52-1.55) for gastric 
adenocarcinoma.  
 
In Paper IV, we defined a dietary pattern characterized by dietary intake of lignans, 
quercetin and resveratrol, the three common phytochemicals with estrogenic properties, 
in a Swedish population-based case-control study. A decreased risk of esophageal 
cancer was found among individuals with a high dietary intake of these three 
phytochemicals. Comparing the highest quintile of food pattern score with the lowest 
quintile, the adjusted ORs were 0.24 (95% CI: 0.12-0.49) for esophageal 
adenocarcinoma, 0.31 (95% CI: 0.15-0.65) for esophageal squamous-cell carcinoma, 
and 0.49 (95% CI: 0.28-0.84) for gastroesophageal junctional adenocarcinoma. 
 
In conclusion, a high dietary intake of phytoestrogens, typically lignans, might decrease 
the risk of adenocarcinoma of esophagus and gastroesophageal junction. The FFQ-97 
can be used to assess lignan exposure, and a dietary pattern characterized by a high 
dietary intake of lignans, quercetin, and resveratrol might prevent esophageal cancer. 
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 1 
1 INTRODUCTION 
 
Esophageal cancer is one of the least studied and deadliest cancers worldwide. There 
are two main histologic types of esophageal cancer: squamous-cell carcinoma and 
adenocarcinoma. Esophageal adenocarcinoma is the dominant histological subtype of 
esophageal cancer in Western society. The abruptly increasing incidence and the strong 
male predominance (3 to 9:1) of esophageal adenocarcinoma have attracted 
considerable attention during the last few decades.1,2 The prognosis of esophageal 
cancer is poor, although surveillance, diagnostic measures and therapy have improved. 
Given the rapidly rising incidence and poor survival, it is important to identify 
potentially modifiable beneficial factors for esophageal cancer, particularly for men.  
 
Dietary phytoestrogens are a group of compounds that naturally occur in plant foods 
with estrogenic properties due to similar chemical structures to endogenous estrogens. 
They have also been observed to have other beneficial effects, such as anti-oxidative, 
anti-carcinogenic and anti-obesity properties.3,4 A number of nutritional 
epidemiological studies have demonstrated the protective role of dietary phytoestrogen 
in several cancers, including breast, prostate, colon and ovarian cancer.5-9 Evidence 
from in vitro as well as in vivo studies has suggested a potential anti-carcinogenic effect 
of phytoestrogen in esophageal tumor cell lines.10 However, no epidemiological study 
has, to the best of my knowledge, investigated the potential association between 
phytoestrogen lignan intake and risk of esophageal cancer. 
 
Given this deficit of epidemiological information about a possible phytoestrogen-
esophageal cancer relation, the aim of this thesis was to clarify the associations of 
phytoestrogen intake with risk of human esophageal cancer, including gastroesophageal 
junctional adenocarcinoma. 
 2 
2 BACKGROUND 
 
2.1 ESOPHAGEAL CANCER 
 
2.1.1 Incidence and trend  
Worldwide, esophageal cancer is the eighth most frequent cancer, with an estimated 
481,000 new cases (3.8% of the total) diagnosed in 2008, and the sixth leading cause of 
death from cancer, with 406, 000 deaths (5.4% of the total).11 However, esophageal 
cancer is mainly a disease of low-income countries, occurring around four times more 
frequently in low- to middle- than in high-income countries. The highest risk areas of 
the world are in southern Africa, with an age-standardized incidence of up to 22.3 per 
100, 000 in men and 11.7 per 100, 000 in women (Figure 1).11 High incidences are also 
reported in the Asian ‘esophageal cancer belt’, stretching from northern Iran through 
the central Asian republic to north-central China. 
 
 
 Figure 1. Esophageal Cancer, World Age-Standardized Incidence Rates, World   
Regions, 2008 Estimates.11  
 
There are two main histological types of esophageal cancer: squamous cell carcinoma 
and adenocarcinoma. Squamous cell cancer arises from the epithelial cells that line the 
upper part of the esophagus, and adenocarcinoma arises from glandular cells that are 
present at the junction of the esophagus and stomach.12 From a global perspective, 
squamous cell carcinoma is the dominant subtype of esophageal cancer, particularly in 
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Asian countries, accounting for over 90% of all esophageal cancer cases.13 High 
incidence areas of esophageal squamous-cell carcinoma include Normandy and 
Bretagne in Europe, and northern China, Japan, India and Iran.14,15 The incidence rates 
of squamous-cell carcinoma have remained stable or decreased in Western countries in 
recent decades.1 Specifically, the overall age-standardized incidence of squamous-cell 
carcinoma in Sweden has dropped from 4.26 per 100,000 in 1973 to 2.13 in 2010 in 
men, and in women from 1.52 to 1.26 per 100,000 (Figure 2).16 Meanwhile, in the 
latter half of the 1980s, it was realized that the incidence of esophageal adenocarcinoma 
was increasing rapidly, especially for men, in many Western populations.17-27 In 
Sweden, the age-standardized incidence of esophageal adenocarcinoma increased from 
0.48 per 100,000 in 1973 to 4.05 in 2010 in men, and in women from 0.16 to 0.62 per 
100, 000 (Figure 2).16 The rapidly increasing incidence of esophageal adenocarcinoma 
is a global phenomenon.2 A recent global assessment of 117, 946 incident cases of 
esophageal adenocarcinoma found that the average annual increase ranged from 3.5% 
in Scotland to 8.1% in Hawaii.28  
 
 
Figure 2.Trends in age-standardized incidence of esophageal cancer per 100, 000 
during 1970 and 2010 in Sweden.16 
 
The gastroesophageal junction forms the border between the distal esophagus and the 
proximal stomach, and normally is where the squamous epithelium of the esophagus 
transitions into the columnar epithelium of the gastric cardia (the Z-line).29 To be 
classified as carcinoma of the gastroesophageal junction, the tumor has to have its 
center within 5 cm proximal and distal of the anatomic gastric cardia.30 The majority of 
neoplasms diagnosed at the gastroesophageal junction are adenocarcinoma. 
Gastroesophageal junctional adenocarcinoma shows similarities with esophageal 
adenocarcinoma in etiology and the anatomical proximity, and therefore they are 
frequently considered together. Gastroesophageal junctional adenocarcinoma is a rare 
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but lethal condition with increasing incidence since the early 1970s. The age-adjusted 
incidence rate consistently increased from 1.22 per 100, 000 person years during 1973-
1978 to 1.94 during 2003-2008 in the USA.31 
 
 
2.1.2 Survival 
Although surveillance, diagnostic measures and therapy have improved, the overall 5-
year survival in patients with esophageal cancer remains lower than 15% in Western 
societies.1 Lagergren et al. reported that relative 5-year survival rates during the two 
recent periods 1990-1999 and 2000-2008 were 12.5% and 10.3% for esophageal 
squamous-cell carcinoma, and 12.5% and 14.6% for esophageal adenocarcinoma in the 
Swedish population.32 Recent data collected from nine Surveillance, Epidemiology, and 
End Results Registries in USA indicate moderate improvements in survival of total 
esophageal cancer, as well as gastroesophageal junctional adenocarcinoma.33,34 The 
cumulative survival of gastroesophageal junctional adenocarcinoma increased from 8% 
to 12% to 17% diagnosed during 1973-1984, 1985-1996, and 1997-2008, 
respectively.31 The data from Sweden also illustrates the similar survival increase of 
gastroesophageal junctional adenocarcinoma from 11.1% to 14.2% during the period 
1990-1999 to 2000-2008.32 These changes might be related to improvements in 
endoscopic detection and in surgical and medical therapy for early-stage disease.35 
 
 
2.1.3 Risk factors in brief  
A summary of risk factors for both histological types of esophageal cancer, and 
gastroesophageal junctional adenocarcinoma are presented in Table 1.36,37 
 
 
2.1.3.1 Adenocarcinoma  
 
Gastroesophageal reflux disease and Barrett’s esophagus 
Gastroesophageal reflux disease is an established strong and dose-dependent risk factor 
for esophageal adenocarcinoma and it affects up to 30% of the Western population on a 
monthly basis.38 Longstanding reflux is the main cause of Barrett’s esophagus, which is 
a precursor to esophageal adenocarcinoma, and the strongest known risk factor for this 
malignancy. Barrett’s esophagus is characterized by the replacement of the normal 
squamous epithelium in the distal esophagus with an intestinal-like specialized 
columnar epithelium.39,40 A recent study found that the relative risk of esophageal 
adenocarcinoma among patients with Barrett’s esophagus was 11.3, compared with the 
risk in the general population.41 
 
 
Obesity 
Obesity is established as an important risk factor of esophageal and gastroesophageal 
junctional adenocarcinoma and it might be the key factor explaining the increasing 
incidence and male predominance of these tumors.42,43 Lagergren et al. found that the 
heaviest quartile of the population had a 7.6-fold increased risk of esophageal 
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adenocarcinoma.44 It should be noted that not only body mass index (BMI), but more 
importantly, visceral obesity is strongly associated with increased risk. Visceral obesity, 
also named as abdominal obesity or central obesity, is the accumulation of abdominal 
fat resulting in an increasing waist circumference. Recent studies indicate that visceral 
obesity increases the occurrence of reflux and Barrett’s esophagus independently of 
BMI.45 Furthermore, visceral obesity is more common in men than in women, which 
might contribute to the male predominance of esophageal adenocarcinoma. A potential 
underlying mechanism is that visceral obesity increases intra-abdominal pressure, 
which leads to increased intra-gastric pressure.  This leads to an increased 
gastroesophageal pressure gradient inducing lower esophageal sphincter relaxation, and 
finally causes gastroesophageal reflux.46,47  
 
 
Tobacco smoking 
Tobacco smoking is a moderate risk factor for esophageal adenocarcinoma and could 
increase the risk at a level ranging from 1.5-fold to 4-fold.35,37,48 A recent meta-analysis 
reported that the pooled risks are approximately 2-fold higher in ever-smokers 
compared to never-smokers.49 Smoking patterns (cigarette consumption and duration of 
smoking) also influenced the cancer risk differently. Compared to never-smokers, those 
who smoked ≥20 cigarettes/day or had a long smoking duration (≥40 years) had a 2.5-
fold increased risk.49 
 
 
Alcohol intake  
The risk of esophageal adenocarcinoma is not or only weakly related to alcohol 
consumption. Although some early studies have found that alcohol consumption is 
associated with an increased risk of esophageal adenocarcinoma,50,51 a recent meta-
analysis provides evidence of an absence of any such association.52 In an earlier study 
based on the same database as Paper I and IV, Lagergren et al. concluded that the risk 
of esophageal adenocarcinoma was not associated with alcohol use.53 Interestingly, it is 
often believed that light or moderate alcohol consumption is associated with a reduced 
risk of esophageal cancer. Those who drank modest levels of wine (<50-90/week) or 
port or spirits (<10-20 g/week) had significantly lower risks of esophageal 
adenocarcinoma in a nationwide Australian case-control study.54  
 
 
Fruit and vegetables  
Several studies have suggested that high consumption of fruit and vegetables could be 
considered as protective factors against esophageal cancer.39,55-59 Low intake of fruit 
and vegetables has been estimated to account for 15.3% of esophageal 
adenocarcinoma.60 Interestingly, the potential beneficial effects of vegetables and fruit 
may be specific to certain groups, including dark green, leafy green or raw vegetables, 
raw fruits and citrus fruits.55,61-64  
 
 
Fiber intake 
Dietary fiber intake has been widely suggested as a strong and independent beneficial 
factor in the development of esophageal adenocarcinoma.58,62,65-68 It may have 
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protective effects via a mechanical action by helping to remove and/or limit the contact 
of carcinogens with the esophageal epithelium.69 In addition, high-fiber foods generally 
tend to have a higher content of antioxidants and phytochemicals.70,71  It has also been 
hypothesized that high-fiber intake may reduce the risk of hiatal hernia, erosive 
esophagitis and reflux symptoms, which have been implicated as risk factors for 
esophageal adenocarcinoma.68,72 Particularly cereal fiber, representing a major source 
of fiber intake (>60%) in Swedish population, plays a major protective role in the 
etiology of esophageal adenocarcinoma.73  
 
 
Fat and meat 
Several studies based on Western populations reported an increasing risk of esophageal 
adenocarcinoma following high consumption of total meat or red meat. However, these 
results were not statistically significant.63,64,66,68,74 In terms of processed meat, Gonzales 
et al. reported a 3-fold increased risk of adenocarcinoma among those with high 
consumption, using the data from the EPIC cohort.74 One of the largest case-control 
studies in UK suggested that total fat, saturated fat, and mono-unsaturated fat intakes 
were adversely associated with risk of esophageal adenocarcinoma.75 It has been 
hypothesized that high dietary fat intake might exert harmful effects by inducing a 
significant increase in taurine-conjugated bile acids in the bile juice, and by increasing 
the pH in the esophagus, as well as by increasing the frequency of transient lower 
esophageal sphincter relaxations.76-78 El-Serag et al. have supported these hypotheses 
by reporting that high dietary fat intake was associated with an increased risk of erosive 
esophagitis and reflux symptoms in a cross-sectional study.72 
 
 
Phytoestrogens  
Studies on phytoestrogen intake and esophageal cancer are sparse. A large scale case-
control study in USA observed a 57% decreased risk of esophageal squamous-cell 
carcinoma with greater isoflavone consumption.79 No association between isoflavone 
intake and esophageal adenocarcinoma was detected, though. However, another study 
in USA indicated a reduced risk of Barrett’s esophagus, a precursor of esophageal 
adenocarcinoma, comparing the highest tertile of isoflavone intake with the lowest 
category.80  
 
 
Sex hormones and reproductive factors 
The female sex hormones, mainly estrogens, have been postulated to play a protective 
role in the etiology of esophageal cancer.81  Estrogen might exert protective effects via 
estrogen receptors, which have been observed in esophageal tissue. However, only a 
few epidemiologic studies have addressed this hypothesis and most of the available 
studies have failed to reveal any such associations. In population-based studies, no 
influence of hormone replacement therapy,82  other estrogen therapy,83 or 
childbearing84 have been reported. However, breastfeeding has been found to be a 
protective factor,57 while high parity and low age at first delivery were also indicated to 
be beneficial from this respect.85,86 In a recent pooled analysis combining data from 
several large case-control studies, a reduced risk of esophageal and gastric junctional 
adenocarcinoma was confirmed among women who breastfed and the risk decreased 
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with increased duration of breastfeeding.83 The potential influence of other endogenous 
reproductive factors, such as menstruation, history of pregnancy, and exogenous 
factors, including use of hormone replacement therapy and of oral contraceptives 
however were not found in that study.83  
 
 
Other risk factors 
High socioeconomic status, male gender,87 Caucasian race88 have also been reported to 
increase the risk of esophageal adenocarcinoma. H. pylori infection has shown to have 
a protective role against esophageal adenocarcinoma.89 
 
 
2.1.3.2 Squamous-cell carcinoma 
Numerous epidemiologic studies have established that alcohol consumption and 
tobacco smoking are causal risk factors for esophageal squamous-cell carcinoma.90,91 
Alcohol, by virtue of its oral intake, will reach every cell of the body; nevertheless, 
some of the effects on the gastrointestinal tract are direct. After consumption, alcohol is 
metabolized by oxidation to acetaldehyde, which has direct carcinogenic and mutagenic 
effects by modifying DNA via generation of DNA adducts.92 In Western countries, 
about 90% of esophageal squamous-cell carcinomas are considered to be caused by a 
combination of alcohol consumption and tobacco smoking.93 Among heavy drinkers 
(≥12 drinks per week), relative risks (RRs) range from 2.9 to 7.4,48,94 while a recent 
meta-analysis showed that moderate consumption (≤7 drinks per week) was associated 
with 30% increased risk of esophageal squamous-cell carcinoma.95 In addition to 
alcohol, smoking greatly increases the risk of squamous-cell carcinoma. Prospective 
epidemiologic data observed a 5-fold higher risk among smokers compared to 
nonsmokers, with risk for heavy smokers increasing nearly 10-fold.48 Furthermore, 
many case-control studies have shown synergistic effects of alcohol and tobacco 
smoking in the development of esophageal squamous-cell carcinoma.37,96  
 
Early evidence from case-control studies show moderate (20-60%) reductions in risk 
with high compared with low fruit and vegetable consumption.56,97 Recently, a meta-
analysis study reported that the highest intake of both vegetables and fruit can decrease 
the risk by 50% in contrast with lowest intake. They also observed a non-linear 
association for intake of both fruit (Pnon-linearity<0.001) and vegetables (Pnon-
linearity=0.04).98 Together with the evidence present in reviews and meta-analysis, there 
is very strong consistency in the evidence for a protective role of fruit and vegetables in 
squamous-cell carcinoma. Of note, pickled vegetables, widely consumed in China, 
have been suggested as a potential risk factor for high incidence of squamous-cell 
carcinoma in this area.99,100 The effect of tea and coffee intake on squamous-cell 
carcinoma is unclear.101 However, study from East-Asian countries, especially China, 
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Table 1. Summary of current knowledge of risk factors of the development of 
esophageal cancer.36,37 
↑↑↑ Strong positive association; ↑↑ moderate positive association; ↑ weak positive 
association; ↓ slightly decrease; ? ambiguous studies; -- no association 
 
indicated that green tea is protective.102-104 The consumption of hot drinks and foods 
has been suggested as a moderate risk factor for esophageal squamous-cell 
carcinoma.101 Thermal injury may cause esophageal cancer via both direct and indirect 
pathways. Directly, thermal injuries can impair the barrier function of the esophageal 
epithelium, which may increase the risk of damage from exposure to intraluminal 
carcinogens. Indirectly, thermal injury could also induce inflammation associated with 
chronic irritation of the esophageal mucosa by local hyperthermia, and consequently 
might stimulate the endogenous formation of reactive nitrogen species and 
nitrosamines.105 Achalasia is another well-established risk factor for squamous-cell 
carcinoma by causing mucosa injures and it causes a 15-fold increased risk of 
squamous-cell carcinoma.106-108 Achalasia is a motor disorder of the lower esophageal 
sphincter, characterized by aperistalsis and failure of the lower esophageal sphincter to 
relax on swallowing, leading to stagnation of food debris and fluid in a dilated 
esophagus.107,108 
 
 
2.2 PHYTOESTROGENS AND HUMAN HEALTH 
Since phytoestrogen lignans are the main contributors of phytoestrogen intake in 
Western populations, the main focus of the current thesis is lignans. 
 
 Esophageal 
adenocarcinoma 
Gastroesophageal 
junctional 
adenocarcinoma 
Esophageal 
squamous-cell 
carcinoma 
Age ↑↑ ↑↑ ↑↑ 
Male gender ↑↑ ↑↑ ↑ 
Caucasian race ↑ ↑ ↓ 
Reflux ↑↑↑ ↑↑ -- 
Barrett’s esophagus ↑↑↑ ↑↑ -- 
Obesity ↑↑↑ ↑↑ -- 
H pylori infection ↓ ↓ ? 
Achalasia -- -- ↑ 
Low socioeconomic 
status 
↓ ↓ ↑ 
Alcohol -- -- ↑↑ 
Tobacco  ↑ ↑ ↑↑ 
Fruit and vegetables ↓ ↓ ↓ 
Cereal fiber ↓ ↓ -- 
Fat and meat ↑ ↑ -- 
Hot beverages ↑ ↑ ↑↑ 
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2.2.1 Classification and food sources 
Phytoestrogens are naturally occurring hormone-like compounds found in plant foods 
which have a unique diphenolic structure. During the 1990s, phytoestrogen-containing 
food and food supplements with soy or red clover components became increasingly 
popular as a substitution for the well-established, but controversial pharmacological 
hormone replacement therapy (HRT). Due to their similarity in chemical structure in 
human female hormone 17β-estradiol, phytoestrogens have the ability to bind to 
estrogen receptors (ER) and therefore act as estrogen agonists or antagonists by 
competing for estradiol and receptor complexes.109,110  Many epidemiologic and 
experimental studies have suggested protective effects of phytoestrogens against 
various estrogen-related diseases, including cardiovascular diseases (CVD),111,112 breast 
cancer,6,113,114 prostate cancer,8,115 and colon cancer.9  
 
Phytoestrogens are subdivided into three main classes: ①	isoflavones, ②	lignans and ③	
coumestans (Figure 3).116 ①	Isoflavones are primarily found in soybeans, red clover 
and other food legumes and nuts.117 The richest food source soybean contains about 1g 
of isoflavones per kilogram fresh weight.118 Genistein, daidzein and glycitein are 
mainly obtained from soy intake, while red clover contains the isoflavones biochanin A 
and formononetin.118 The traditional Asian diet comprises a great amount of soy 
products, such as tofu, soya milk, and miso soup. In contrast, the Western population 
rarely consumes soy produces, and hence obtains isoflavones primarily from other 
legumes, sprouts, and vegetables. Furthermore, in some Western countries, such as 
Finland and Denmark, soy proteins are added into a variety of foods, e.g. cheese, pasta, 
salad dressing, hotdogs, meat products and bread. ②	Dietary plant lignans constitute the 
dominant form of phytoestrogen intake in Western populations. They were first 
detected in humans in 1979 and occur mainly in seeds such as flaxseed, and sesame 
seed, but in Western society, the major food sources of lignans are whole-grain cereals, 
beans, other vegetables, some fruits and berries, wines, particularly red wines,117,119 tea 
and coffee.120 Secoisolariciresinol (SEC) and mataireinol (MAT) are two initially 
identified plant precursors.121,122 More recently, pinoresinol (PIN), lariciresinol (LAR), 
syringaresinol (SYR), and medioresinol (MED) were identified. In the Finnish diet, the 
main sources of SEC are fruit and berries, whereas MAT is mostly derived from whole 
grains, mainly rye.123 Whole grain is a rich source of PIN, SYR and LAR, and PIN is 
also highly present in olive oil.124,125 ③	Coumestrol, uncommon in the diet, is found in 
clovers, soy-bean sprouts and in large amounts in mung-bean sprouts.116 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Classification of phytoestrogens. 
Isoflavones Lignans Coumestans
 Genistein 
 Daidzein 
 Glycitein 
 Biochanin A 
 Formononetin 
 SEC MAT  PIN  LAR  SYR  MED
Phytoestrogens 
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2.2.2 Metabolism  
 
2.2.2.1 Lignans 
After digestion, plant lignans are converted into two major mammalian lignans: 
enterolactone (ENL) and enterodiol (END), by gut microflora in the proximal 
colon.126 The present view of the metabolism of lignans in the gut is presented in 
Figure 4. PIN is converted to LAR and further metabolized to SEC and MAT, which 
are then converted into ENL and END, respectively. END is oxidized to ENL. SRY is 
also metabolized into END and then ENL. ENL is the most abundant lignan 
metabolite in human blood and urine, and its concentration is assumed to reflect 
recent and habitual intake of dietary plant lignans.127,128 Serum ENL concentrations 
and urinary ENL excretion are widely used as biomarkers of plant lignan intake. 
 
Considerable interindividual and intraindividual variations have been observed in 
various populations.122,129 It has been suggested that individual variations in the 
metabolism of plant lignans into mammalian ENL is partly explained by lifestyle and 
diet.130 Smoking and high fat intake decrease the plasma ENL, while constipation, 
intake of whole-grain bread, vegetables, berries and fruits increase the concentration.130 
More importantly, activity of the gut microflora is known as a very influential factor.131 
Therefore, use of antibiotics dramatically decreases the plasma ENL by reducing the 
amount of colonic bacteria.132 
 
 
       
       Pinoresinol                   Lariciresinol           Secoisolariciresinol                Matairesinol   
 
                                            
          
 
 
 
 
 
      Syringaresinol                               Enterodiol                       Enterolactone                                               
 
Figure 4. Metabolism of plant lignans to END and ENL.124,126 
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2.2.2.2 Isoflavone 
Isoflavones are present predominantly as glucosides in most commercially available 
soya products.133 The major glycosides found in soya beans are daidzin, genistein and 
glycitin. Upon consumption, these glucose-conjugated compounds are hydrolyzed by 
mammalian enzyme β-glucosidase or by the gut microflora to form the active 
isoflavone compounds daidzein, genistein and glycitein (Figure 5).133 Daidzein is 
further converted by the intestinal microflora into the estrogenic compouds equol and 
O-desmethylangolensin. There is large intra- and inter-individual variation in the level 
of isoflavone metabolism, and only 23-35% of the individuals in Western populations 
and 50-55% of Asian populations are able to convert daidzein to equol.134  
 
Bioavailability of isoflavone varies among individuals and depends on many factors, 
including dietary habits,135 duration of soy consumption,136 different individual 
metabolism patterns that might be determined by genetic factors,137 different bacterial 
flora,138,139 and gut transit time.135 A rapid gut transit time increases bioavailability, 
whereas a fiber-rich diet decreases the absorption of isoflavones.135 Equol production is 
also influenced by diet,135 showing a higher level of formation in a high carbohydrate 
environment , but a lower level after use of antibiotics.140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Metabolism of isoflavones after digestion.141 
 
 
 
Genistin Genistein
Daidzin Daidzein Equol 
Glycitin Glycitein 
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2.2.3 Potential mechanisms of action of lignans 
 
2.2.3.1 Estrogenic and anti-estrogenic effects  
Due to the similar chemical structure to 17-β estradiol, mammalian lignan ENL may act 
as a weak estrogen agonist or antagonist, and numerous studies have demonstrated this 
biphasic nature of ENL in vitro and in vivo. These divergent results are difficult to 
explain, but it has been suggested that the estrogenic or anti-estrogenic effect of lignans 
depend on the level of endogenous estrogens.142  
 
1. Activation of estrogen receptors 
The lignan ENL has been shown as a very weak ER agonist and binds to the estrogen 
receptors, with preference for ERα and very little for ERβ.143,144 At a physiological ≤1 
µm concentration, ENL has a stimulatory effect on cell growth on estrogen dependent 
cell lines MCF-7 and T47D in the absence of estradiol, but in the presence of a slightly 
stimulatory or non-stimulatory concentration of estradiol, ENL did not cause any 
stimulation but sometimes a slight inhibition.145 More specifically, ENL has been 
observed to mildly increase estrogen-responsive pS2 protein expression.146 
 
2. Effects of lignans on steroid metabolizing and other enzymes  
Lignans have been shown to inhibit enzymes involved in steroid synthesis, including 
aromatase, 5-α-redutase, and 17-β-hydroxysteroid dehydrogenase. Aromatase, also 
called estrogen synthetase, is an enzyme responsible for the conversion of androgens to 
estrogens. ENL has been observed as a moderate inhibitor of placental aromatase, and 
also in several other cell lines.147-149 17-β-hydroxysteroid dehydrogenase is the enzyme 
responsible for the conversion of estrone to estradiol and androstenedione to 
testosterone. Both ENL and END decrease the activities of aromatase and 17-β-
hydroxysteroid dehydrogenase in MCF-7 cells, and inhibit the production of estrone 
and estradiol.150 
 
3. Stimulation of sex hormone binding globulin production (SHBG) 
It has been observed that urinary ENL in women is positively associated with SHBG, 
and negatively with the plasma percentage of free estradiol and free testosterone.151,152 
However, it should be noted that this stimulation on SHBG was found at lower 
physiological concentrations but inhibition at higher.153 An increase of SHBG will 
result in a decreased percentage of free or unbound estradiol or testosterone, which are 
biologically active and are able to enter a cell and activate its receptor. 
 
 
2.2.3.2 Antioxidant activity 
ENL and END have shown antioxidant activity in vitro only at supraphysiological 
concentrations.154,155 In addition, SEC was observed to inhibit the activation of 
polymorphonuclear leukocytes in a concentration-dependent manner and has nearly 
five times the antioxidant potency as compared to vitamin E.156  
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2.2.3.3 Anti-obesity activity 
Experimental studies have found that lignans have effects that act against adiposity. 
ENL has been found to reduce blood lipids and leptin, and induce adiponectin 
expression in mice,157 which might result in reduced risk of esophageal cancer. Cell 
line research has shown that high exposure to leptin is associated with an increased risk 
of Barrett’s esophagus and such exposure can also promote proliferation of EA cells,158 
while high concentrations of adiponectin have shown opposite effects.159  
 
 
2.2.3.4 Inhibition of growth factors 
High plasma levels of insulin-like growth factor I (IGF-I) have been linked to increased 
risk of several cancer types, including esophageal cancer.160 In vivo, an intake of 
flaxseed or purified SEC diglycoside in rats reduced plasma concentration of IGF-I.161 
ENL was also detected to inhibit IGF-I signaling in several cancer cells, such as 
prostate cancer and breast cancer.162,163 
 
 
2.2.4 Lignans and gastrointestinal cancer  
Although experimental studies have demonstrated a protective role of phytoestrogen 
lignans in the development of gastrointestinal cancer, limited evidence is available from 
observational studies (Table 2). 
 
 
Esophageal cancer 
 
Esophageal adenocarcinoma and gastroesophageal junctional adenocarcinoma are 
characterized by a strong male predominance that remains to be explained.21 Estrogens 
have been suggested to contribute to this pattern.83 The beneficial effects of lignans on 
esophageal and gastroesophageal junctional adenocarcinoma might be attributed to 
their potential estrogenic property. The estrogenic effects of lignans are widely 
assumed to be mediated by the mammalian metabolite ENL and via activating ERs.164 
Evidence from previous studies suggest that the protective effect of estrogen on 
esophageal cancer is mediated by the ERs.165 Since the presence of ERs has been 
identified in esophageal tissue,166,167 a linkage between mammalian lignans and 
esophageal cancer via ERs is possible. In addition to their potential estrogenic 
properties, lignans have been demonstrated to attenuate high-fat diet-induced fat 
accumulation and influence serum levels of adipose tissue related hormones, such as 
leptin and adiponectin.157 Cell line research has shown that high exposure to leptin is 
associated with an increased risk of Barrett’s esophagus and such exposure can also 
promote proliferation of esophageal adenocarcinoma cells,158 while high concentrations 
of adiponectin have shown opposite effects.168 ENL has been found to reduce blood 
lipids and leptin, and induce adiponectin expression in mice.157 
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Colorectal cancer 
 
In 1984, Adlercreutz suggested that lignan intake might be protective with regard to 
colon cancer.169  Since then, the majority of studies investigating the role of lignans in 
colon carcinogenesis have been either in vitro or animal study. A recent study observed 
that at 100 microM concentration, both ENL and END significantly reduced the 
proliferation of all four studied colon cell lines (LS174T, Caco-2, HCT-15, T-84).170  
Moreover, lignan-rich foods including flaxseed and rye bran were also observed to 
protect against colon cancer or formation of colon polyps.171,172 
 
To date, only 6 studies have investigated the potential effect of plant lignans,173-175 or 
mammalian enterolignans,9,176,177  in the development of colon cancer. All three studies 
addressing lignan intake exposure indicated lignans’ beneficial role. Heather W. et al. 
calculated the enterolignans intake from animal origin such as meat, seafood and 
nonmilk dairy and reported that high intake of ENL and total enterolignans (ENL, 
equol) was associated with reduced risk of colon cancer by approximately 70% among 
women.175 Although the plant lignan intake seemed to be protective, evidence based on 
a biomarker of enterolignans did not fully support this potential function. In a 
prospective study, the overall relationship between plasma enterolignans and colorectal 
cancer in the full study was null, but there was evidence of increased risk among 
particular subgroups: current smokers, overweight, and women, particularly 
postmenopausal women.177 In contrast, a case-control study reported that higher 
concentration of plasma ENL was associated with lower risk of colon cancer among 
women but higher risk of rectal cancer among men.9  
 
 
Gastric cancer 
A prospective study using data from EPIC was the only available study evaluating 
lignan intake and gastric cancer. During an average follow-up of 11 years, 683 incident 
cases of gastric cancer were identified.178 The mean intakes of lignans were 1640 
µg/day and 1400 µg/day for men and women, respectively. No statistically significant 
association was found for lignan intake and gastric cancer risk. 
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Table 2. Summary of studies investigating lignan exposure in relation to risk of colon and gastric cancer. 
 
Study Study 
design 
Cases/ total 
cohort or 
controls 
Exposure measurement OR/RR/IRR (95% CI)* Adjustment 
Colon cancer 
Michelle Cotterchio 
(2006)/USA173 
 
population-
based case-
control 
1095/1890 FFQ
Intake: plant lignans (SECO, MAT): 
T3 ( >1338 µg /day)  vs. T1( 0-531 µg 
/day)
0.73 (0.56, 0.94) Age, sex, and total energy intake. 
Heather Ward 
(2010)/UK175 
 
nested case-
control 
 
221/886 7-day diet diaries;
Intake:  
1) plant lignans (SECO, MAT): 
continuous  value 
2) enterolignans (ENL, equol): 
continuous  value
Men:
plant lignans: 1.07 (0.73, 1.57); enterolignans 0.94 (0.53, 1.67); 
ENL: 1.00 (0.66, 1.66) 
Women: 
plant lignans: 1.52 (0.88, 2.64); enterolignans 0.32 (0.13, 0.79); 
ENL: 0.33 (0.14, 0.74) 
Age, height, weight, family history of colorectal 
cancer, smoking status, aspirin use, physical 
activity, and average daily intake of fat, energy, 
calcium, fiber, alcohol, and red and processed 
meats. 
Raul Zamora-Ros 
(2012)/Spain174 
 
hospital-
based case-
control 
424/401 600-item FFQ;
Intake: plant lignans (SECO, MAT, 
LAR, PIN): Q4 ( > 500 µg/ 1,000 kal 
day) vs. Q1( <270 µg/ 1,000 kal day) 
0.52 (0.28-0.96) 
Age, sex, BMI, energy intake, alcohol and fiber 
intake, red and processed meat intake, tobacco 
consumption, physical activity, regular drugs 
(aspirin, non-steroidal anti-inflammatory drug, 
both, none), and family history of colorectal 
cancer.
Heather Ward 
(2008)/UK176 
 
nested case-
control 
 
221/889 Serum and urine
END, ENL: continuous  value 
 
Serum
END: 1.04 (0.99-1.09); ENL: 1.02 (0.95-1.10); 
Total lignans: 1.03 (0.94-1.12) 
Urine 
END: 1.04 (0.99-1.09); ENL: 1.02 (0.95-1.10); 
Total lignans: 1.03 (0.94-1.12)
Age, sex, height, weight, and average intake of 
fiber and calcium.  
 
Anneleen Kuijsten 
(2008)/Netherland177 
 
nested case-
control 
 
160/387 Plasma
END: Q4 (≥ 1.96 nmol/L) vs. Q1 
(<0.45 nmol/L); 
ENL: Q4 (≥ 18.7 nmol/L) vs. Q1 
(<4.11 nmol/L); 
 
END: 1.11(0.56-2.20) 
ENL: 1.70 (0.88-3.27) 
Age, sex, study center, BMI, alcohol, smoking 
status, duration of smoking, physical activity 
during leisure time and at work, aspirin use, 
education level, intake of energy, fiber, calcium, 
meat, fish, fruit, vegetables, tea, wine, and whole 
grain bread.
Nina Føns Johnsen 
(2010)/Denmark9 
 
nested case-
control 
 
244/370 Plasma 
ENL: continuous values 
 
 
Colon cancer
Women: 0.73 (0.56-0.94) 
Men: 1.19 (0.93-1.51); 
Rectal cancer 
Years of education, baseline values of present use 
of hormone replacement therapy, use of non-
steroidal anti-inflammatory drugs, BMI, present 
smoking, bowel movements per week, intake of 
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Women: 0.83 (0.57-1.20) 
Men: 1.74 (1,25-2.44); 
red and processed meat, alcohol and whole grain 
products.
 
Gastric cancer 
Zamora-Ros R 
(2012)/ Europe178 
Cohort study 683/477,312 FFQ
Plant lignans (SECO, MAT, LAR, PIN, 
ENL, ENT) 
Men: Q4 (>2.1 mg/day) vs. Q1 (<1.0 
mg/day) 
Women: Q4 (>1.7 mg/day) vs. Q1 
(<0.9 mg/day) 
 
Men:
0.99 (0.63, 1.55) 
 
Women:  
0.94 (0.54, 1.64) 
Age, sex, center, education level, smoking status, 
physical activity, BMI, alcohol and energy intake, 
and daily consumption of fruit, vegetables, and red 
and processed meat. 
* OR: odd ratio; RR: relative risk; IRR: incidence rate ratio 
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2.3 QUERCETIN, RESVERATROL AND HUMAN HEALTH 
 
Quercetin 
Quercetin is a flavonol found in a variety of human foods such as onions, grapes, 
apples, berries, cherries, broccoli, citrus fruits and tea. Quercetin is known for its wide 
range of biological effects such as anti-oxidative effects,179 increasing lipolysis,180 
inducing apoptosis181 as demonstrated by animal studies. The idea that quercetin 
might also exert anti-cancer effects has also been confirmed by in vitro and in vivo 
studies.181,182 
 
 
Resveratrol 
Resveratrol is a naturally occurring polyphenol found mainly in grapes, a variety of 
berries, peanut, and medical plants. The most important dietary source of resveratrol 
is red wine, and the containing resveratrol is usually postulated to be the important 
factor for the beneficial effect of red wine for human health.183  Resveratrol has 
received considerable attention since 1997 for its various pharmacological effects, 
including anti-oxidant, anti-cancer, anti-inflammatory and anti-platelet properties.184-
186 It has also been shown to reduce the synthesis of lipids by repression of PPARγ in 
differentiate adipocytes, suppress proliferation and induce apoptosis.187-189 
 
 
 
2.4 SYNERGISTIC EFFECTS BETWEEN PHYTOCHEMICALS 
 
Quercetin, resveratrol and lignans are the most widely studied phytochemicals in 
Western population due to their potential beneficial effect on human health. Quercetin 
has been reported to increase lipolysis in rat adipocytes and induction of 
apoptosis.180,190  Resveratrol has also been shown to reduce the synthesis of lipids in 
rat liver and play an important role in suppressing proliferation, and inducing 
apoptosis in hematopoietic cells in vitro.189 Interestingly, the combined intakes of 
phytoestrogen isoflavone, quercetin and resveratrol were observed with synergistic 
effect in suppression of adipogenesis and induction of apoptosis in an animal study.191 
These evidences provide a valid rationale to evaluate the beneficial role of total intake 
of these phytochemicals in the development of esophageal cancer. Since isoflavone is 
the major phytoestrogen source in Asian diet, while lignan is the dominant 
phytoestrogen intake among Western population, the current thesis will focus on 
lignan intake instead of isoflavone. 
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3 AIMS OF THE STUDIES 
Based on the evidence from experimental studies, dietary intake of phytoestrogens 
lignans and in combination with other phytochemicals quercetin and resveratrol could 
protect against esophageal cancer. However, none of the current epidemiological 
studies has demonstrated this possible phytoestrogen-esophageal cancer relation. In 
this thesis, we aimed mainly to investigate whether dietary intake of phytoestrogen 
lignans could influence the risk of esophageal cancer in the Swedish population.  
 
 
Paper I           To determine the association between dietary intake of lignans and risk 
of esophageal cancer in a Swedish population-based case-control study. 
 
Paper II          To validate the use of a food frequency questionnaire for the 
assessment of dietary intake of lignans compared to the serum biomarker 
enterolactone. 
 
Paper III         To clarify whether dietary intake of lignans is associated with the risk 
of esophageal and gastric adenocarcinoma using a prospective design. 
 
Paper IV         To define a food pattern characterized by high intake of the 
phytochemicals lignans, quercetin and resveratrol, and to evaluate the association of 
this food pattern in relation to risk of esophageal cancer. 
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4 MATERIAL AND METHODS 
 
 
4.1 SUBJECTS AND STUDY DESIGN 
 
The Swedish Esophageal and Cardia Cancer Study 
 
The nationwide Swedish Esophageal and Cardia Cancer study (SECC)38 was a 
population-based case-control study that enrolled subjects younger than 80 years, 
born and living in Sweden from December 1, 1994, through December 31, 1997 
(Figure 6). All newly diagnosed patients with esophageal or gastroesophageal 
junctional adenocarcinoma, and half of those with esophageal squamous cell 
carcinoma (those patients born on even-numbered days) were eligible as cases. The 
reasons for reducing the number of esophageal squamous cell carcinoma were three: 
1) The main objective of the study was to investigate risk factors of the 
adenocarcinomas, 2) The incidence of squamous cell carcinoma was higher than that 
of adenocarcinoma during the inclusion period, and 3) Cost-efficiency reasons. The 
study included extensive personal interviews with all participants.  
 
A comprehensive organization for the rapid ascertainment of cases was used to ensure 
that every potential case patient throughout the country was identified soon after 
diagnosis. The organization included contacting persons at all 195 departments of 
general surgery, thoracic surgery, otorhinolaryngology, oncology, and pathology in 
Sweden, as well as continuous collaboration with the six regional tumor registries. 
Age- (within 10 years) and sex-matched controls were selected randomly by Statistics 
Sweden from the subjects in the entire Swedish population using the Swedish 
Register of Total Population. The numbers of controls selected in each defined 
stratum were adjusted to approximate the age and sex distribution of the patients with 
esophageal adenocarcinoma. All cases and controls were personally interviewed by 
professional interviewers from Statistics Sweden, who were taught to treat cases and 
controls in a strictly similar manner. The participants were asked about background 
data and exposure to established etiological factors, which have been addressed in 
detail in separate publications, including gastroesophageal reflux,38 obesity,44 tobacco 
smoking,53 alcohol drinking,53 education,192 physical activity,44 childbearing,193 and 
Helicobacter pylori infection.194 Data on infection with Helicobacter pylori was 
assessed by serology from blood samples, which were collected from a majority of 
the cases and controls, as presented in detail elsewhere.194  The SECC database was 
used for Paper I and IV of the thesis. 
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Figure 6. Study population for Paper I and IV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Swedish Mammography Cohort 
 
The Swedish Mammography Cohort (SMC) was established between 1987 and 1990, 
when all women born between 1914 and 1948 residing in two counties in central 
Sweden Västmanland (n=41,786) and Uppsala counties (n=48,517) were invited to 
participate in a population-based mammography screening program (Figure 7). The 
invitation letter was accompanied by a questionnaire (the FFQ-87 with 67 food items) 
that asked for information on dietary factors, weight, height, education level, and 
Swedish subjects <80 years old living 
in Sweden during 1994-1997 
Questionnaire sent to all participants 
Cases ascertainment organization 
 195 clinics 
 6 regional tumour registries 
 
Control selection 
 Randomly selected from 
entire Swedish population 
 Age (within 10 years), and 
sex-matched 
Eligible cases (n=757) 
 216 esophageal 
adenocarcinoma 
  228 esophageal squamous-
cell carcinoma 
 313 gastroesophageal 
junctional adenocarcinoma 
Controls (n=1128) 
Personal interview by professional interviewers 
Recruited cases (n=618, participate rate 
82%) 
 189 esophageal adenocarcinoma 
 167 esophageal squamous-cell 
carcinoma 
 262 gastroesophageal junctional 
adenocarcinoma 
Recruited controls (n=820, 
participate rate 73%) 
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family history of cancer.195 A total of 66,651 women (74% of all eligible) returned a 
completed questionnaire. From the baseline cohort, we excluded participants with 
incorrect or missing personal identity numbers, missing date on the questionnaire, 
date of migration, or date of death. Additional exclusion was also applied for women 
who had previous cancer diagnosis, consumed implausibly low or high energy intake, 
and who died or moved out of the study area between baseline and autumn 1997. A 
total number of 10,621 women were excluded based on the above criteria. In the 
autumn of 1997, an expanded questionnaire (the FFQ-97 with 93 food items) with 
about 350 items concerning diet, other lifestyle factors, and medical history was 
mailed to all women who were still alive and residing in the study area (n=56,030). 
Among them, 39,227 women (70% of eligible) completed the questionnaire, 2530 of 
whom were further excluded due to incorrect personal identity number, implausible 
energy intake and cancer diagnosis before January 1998. The FFQ-97 elicited 
information on weight, height, waist and hip circumferences, diet, and lifestyle 
factors. 
 
During 2003-2004, 140 women aged 55 to 75 years were randomly selected from the 
SMC for Paper II (Figure 7). None of them had used antibiotics in the past year. 
This exclusion was necessary since antibiotics are known to influence phytoestrogens’ 
metabolism. All 140 participants answered the FFQ-87 and the FFQ-97 in 2003-2004, 
and fasting blood samples were collected within 3 months of completing these 
questionnaires. The information on history of gastrointestinal disease was obtained 
from the National Patient Register, while the diabetes data was collected from the 
combination of the National Patient Register, the National Diabetes Register and self-
reported questionnaires.  
 
 
The Cohort of Swedish Men 
 
The Cohort of Swedish Men (COSM) began in the autumn of 1997, when 48,850 men 
(49% of all eligible) born between 1918 and 1952 and residing in two counties in 
central Sweden (Västmanland and Örebro counties) answered a mailed questionnaire 
that was identical (except for some sex-specific questions) to the SMC questionnaire 
in 1997 (FFQ-97) (Figure 7). Men (n=3877) with wrong or missing personal identity 
numbers, those with implausibly low or high total energy intake (i.e., three standard 
deviations from the mean value) and those with cancer (except non-melanoma skin 
cancer) diagnosed before enrollment or during the first year of follow-up were 
excluded.  
 
Eligible participants for Paper III were those women and men who completed the 
1997 questionnaire after exclusion, leaving 36,697 women from SMC and 44, 973 
men from COSM for the analysis.  
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Figure 7. Study population for Paper II and III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMC Population (1987-1990) 
90,303 women born 1914-48, residing 
in Västmanland and Uppsala counties 
                      (FFQ-87) 
 
    66,651 respondents (74%) 
Excluded (n=10,621) 
 Incorrect or missing personal 
identity number 
 Missing date on 
questionnaire, date of 
migration, or date of death 
 Implausibly low or high total 
energy intake 
 Previous cancer diagnosis  
 Died or moved out of the 
study area between baseline 
and autumn 1997 
Second questionnaire sent to 
56,003 women 
                  (FFQ-97) 
    39,227 respondents (70%) 
COSM population (1997) 
100,303 men born 1918-52, residing in 
Västmanland and Uppsala counties 
                   
                        (FFQ-97) 
    48,850 respondents (74%) 
Excluded (n=2530) 
 Incorrect or missing personal 
identity number 
 Implausibly low or high total 
energy intake 
 Cancer diagnosis before 
January 1998 
Excluded (n=3877) 
 Incorrect or missing personal 
identity number 
 Implausibly low or high total 
energy intake 
 Cancer diagnosis before 
January 1998 
Study population for Paper III 
36,697 women and 44,973 men         
 
140 
random 
healthy 
women for 
Paper II 
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4.2 EXPOSURE MEASUREMENT  
 
4.2.1 Dietary assessment of lignans and other nutrients intake 
Paper I & IV: 63-item FFQ 
Dietary habits were assessed by use of a written validated FFQ concerning the 
habitual intake of 63 foods and beverages.196 The questionnaires were distributed 
before the face-to-face interviews with professionals from Statistics Sweden, and the 
given answers were checked during the interview. Missing answers or other 
uncertainties in questionnaires were as far as possible completed and clarified during 
these interviews. The FFQ examined dietary habits 20 years before the interview, with 
the purpose of obtaining a plausible induction time between the exposure and the 
invasive cancer. The frequency of intake of each food item was assessed on the basis 
of open answers, i.e., number of times of consumption per day, week, month or year. 
A detailed list of food items stratified by 26 food groups is shown in Table 3.197  
 
The calculation of lignan intake included six precursors of mammalian lignans: MAT, 
SECO, LAR, PIN, SYR, and MED. To calculate the intake of specific lignans, we 
categorized the contents of all six precursors in various dietary items based on 
published analytical data.116-118,126,198-202 When multiple values were reported in the 
literature, averages were calculated; when values were given in ranges, midpoint 
values were used. The contents of the lignans LAR, PIN, SYR, and MED in different 
grain flours were used to estimate lignan content of bread and cereal products. 
Different contents of quercetin from onions, broccoli, lettuce, tomatoes, strawberries, 
apples, wine, tea, and fruit juice were accumulated.203-206 The major sources of 
resveratrol were derived from intake of wine, tea, and berries.206-209 Energy contents 
were obtained from the Swedish National Food Administration database.210 The 
exposure of dietary lignans was expressed in nutrient density by dividing the 
estimated daily intake of lignans (µg/day) by the estimated total energy intake 
(MJ/day) according to a Multivariate Nutrient Density Model.211 While calculating 
each food item intake, the frequency of consumption was multiplied by sex-specific 
portion size, using data from the Swedish national diet survey (Riksmaten 1997-
1998).212 
 
 
Table 3. List of food items in food frequency questionnaire used in paper I and IV.197 
 
Food groups Items 
Vegetables Green salad, cauliflower, white cabbage, red cabbage, 
spinach, carrot, onion, leek, garlic 
Tomatoes Tomatoes 
Fruit Citrus fruits, apple, pear, banana, plums 
Whole grains Whole grain bread, crisp bread, soft bread, oatmeal, 
bran 
Refined grains Rice, macaroni, spaghetti, pancakes, waffles 
Cereal Porridge (oatmeal, rice, corn flour, semolina), infant 
cereal, cereal/muesli 
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Low-fat dairy Low fat milk 
High-fat dairy Whole milk, milk powder, cheese, cream, ice cream 
Dressing or sauce Bechamel sauce, béarnaise sauce 
Fish Herring, cod, flat, hake, whiting, haddock, turbot, 
salmon, white fish, eel, pike, perch 
Poultry Chicken 
Red meat Meat ball, pork, beef, liver, minced meat 
Processed meat Smoked salted pork, “Falu” sausages, hamburgers, hot 
dogs, blood sausages 
Eggs Fried eggs, boiled eggs, omelettes 
Potatoes Boiled potatoes, baked potatoes 
French fries French fries, fried potatoes 
Sweets Buns, Danish pastries, cookies, sweet biscuits, tarts, 
cakes, chocolate, jam, marmalade, fruit sauce 
Juice Fruit juice 
High energy drinks Fruit syrup, soft drinks 
Nuts Nuts 
Tea Tea 
Coffee Coffee 
Beer Light beer, median beer, strong beer 
Wine Red wine, white wine 
Liquor Brandy, gin, vodka, rum, whiskey, liqueur 
 
 
Paper II & III: FFQ-87 & FFQ-97 
The FFQ-87 and the FFQ-97 included 67 and 93 food items, respectively. In the FFQ-
87, participants were asked to report their average frequency of consumption of each 
type of food or beverage using 8 predefined frequency categories: ‘never/seldom’, ‘1-
3 times/month’, ‘1 time/week’, ‘2-3 times/week’, ‘4-6 times/week’, ‘1 time/day’, ‘2 -3 
times/day’, or ‘4 times/day’. In the FFQ-97, close-ended questions with similar 
response categories were set for most food items, but open-ended questions (open 
answers, not pre-specified categories) were designed for some commonly consumed 
foods including bread, milk, cheese, soft drinks, beer, coffee, tea and sugar. Total 
lignan intake was estimated by summing up all six of the most prevalent dietary 
precursors of ENL: SEC, MAT, LAR, PIN, MED, and SYR. Of the 67 and 93 food 
items listed in the FFQ-87 and the FFQ-97, 45 (69.2%) and 65 (69.9%) items were 
assigned lignan values, respectively. The remaining had no values assigned because 
the lignan content was assumed to be negligible. Nutrient intake was computed by 
multiplying the frequency of food items by the nutrient content of the age-specific 
servings. The estimations of total intake of lignans were adjusted for total energy 
intake, using the Residual method.213 Since the activity of the gut microflora 
influences the metabolism of dietary lignans to ENL, we also used a formula based on 
experimental results to calculate the expected amount of mammalian lignan ENL in 
Paper II:214  
ENL =0.62*MAT+0.72*SEC+1.01*LAR+0.55*PIN+0.04*SYR+0.8*MED. 
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4.2.2 Analysis of serum enterolactone 
Blood samples were processed and separated for sera that were stored at -80˚C until 
analysis. Samples were shipped frozen to the Folkhälsan Institute for Preventive 
Medicine, Nutrition and Cancer (Helsinki, Finland), where they were thawed and 
subjected to overnight enzymatic hydrolysis and ether extraction. Sample extracts 
were then diluted in assay buffer, with europium-label, internal standards, and 
subsequently analyzed by time-resolved fluoroimmunoassay (TR-FIA) according to 
previously reported protocols for assessment of ENL.215-217 The intra- and inter-assay 
coefficient of variation (CV %) of the TR-FIA method was low (3.3-6.0% and 6.9-
9.9% for ENL, depending upon the serum concentrations).215-217 Serum isoflavone 
genistein was analyzed using the same method, but only 40 of the total 140 women 
had a detectable serum concentration within the range 0-48 nmol/L (median=3 
nmol/L), indicating low consumption of isoflavone genistein. Therefore, genistein 
was not included in the final analysis.  
 
 
4.2.3 Lifestyle factors and other potential confounders 
In addition to dietary habit, the questionnaires also covered various lifestyle indicators 
including e.g. BMI, smoking status, physical activity, education level, and reflux 
symptoms. BMI was calculated as body weight divided by square of the body height 
in meters (kg/m2), and classified into 4 subgroups: <18.5, 18.5-24.9, 25-29.9, or ≥ 30 
kg/m2 in Paper I and Paper IV, 3 subgroups:  <25, 25-29.9, or ≥ 30 kg/m2 in Paper 
II and III. The participants with a BMI of 25-29.9 kg/m2 were considered as 
overweight, while a BMI ≥ 30 kg/m2 represented obesity. Smoking habit was 
classified into: nonsmoker, past smoker, or current smoker. Physical activity was 
categorized into four levels (I-low, II, III, IV-high), using a combination of 12 
variables, reflecting the physical activity level during both leisure time and at work. 
Heartburn and acid regurgitation were considered to be the symptom of 
gastroesophageal reflux (yes/no).  Participations were also asked for the duration of 
years of education, which was classified into 3 levels: ≤ 9, 10-12, and ≥ 13 years.  
 
Paper I and IV: Data on infection with Helicobacter pylori were assessed by 
serology from blood samples, which were collected from the majority of the cases and 
controls, as presented in detail elsewhere.89  
 
Paper II: The information on history of gastrointestinal disease was obtained from 
the National Patient Register, while the diabetes data was collected from the 
combination of the National Patient Register, the National Diabetes Register and self-
reported questionnaires. 
 
 
4.3 CASE ASCERTAINMENT 
 
Paper I and IV 
All newly diagnosed patients with esophageal or gastroesophageal junctional 
adenocarcinoma and half of those with esophageal squamous cell carcinoma were 
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eligible as cases. Uniform routines for tumor classification were introduced at all 
participant sites. A comprehensive organization for rapid ascertainment of cases 
included collaboration with 195 hospital departments and the six regional tumor 
registries. The tumor classification was completed as follows: 
 
1) All patients underwent esophago-gastroscopy. The gastroesophageal junction 
was defined as the point where the proximal longitudinal mucosal folds begin 
in the stomach. 
2) Serial biopsies were performed according to a special protocol in order to 
obtain a correct histo-phathological diagnosis and to determine the exact 
location of the tumor.  
3) Surgeons and the pathologists provided detailed descriptions of the location of 
the cancer on special forms.  
4) Almost all biopsies and surgical specimens were finally re-examined by a 
single experienced pathologist (Anders Lindgren). 
5) For those ambiguous cases, a panel of surgeons and pathologists classified the 
cases, using all available information. 
 
 
Paper III 
All newly diagnosed cases of esophageal and gastric adenocarcinoma were identified 
through linkage to the Swedish Cancer Register, which was established in 1958 and 
has been estimated to be highly complete. The completeness of the registry was 63% 
for esophageal adenocarcinoma, 74% for cardia adenocarcinoma, and 98% for gastric 
cancer.218,219 Ascertainment of death date was accomplished by linkage to the 
Swedish Causes of Death Register and the Swedish Register of the Total Population. 
Cases of esophageal or gastric adenocarcinoma were defined as the first diagnosed 
malignant neoplasm detected since entry into the cohort. We included only cases of 
adenocarcinoma since this is the main histologic type of malignancy in the upper 
gastrointestinal tract and the etiology of adenocarcinomas is different from other 
histological types. Moreover, other histological types of malignant esophageal or 
gastric tumors do not share the unexplained male predominance in incidence. Each 
participant was followed from January 1, 1998 until the date of diagnosis of 
adenocarcinoma of the esophagus or stomach, any other cancer, death, or end of study 
period (December 31, 2009), whichever came first. To avoid detection bias, we 
excluded all persons-years during the first year of follow-up and all participants 
diagnosed with any cancer during the first year of follow-up. Due to the similar 
etiology and pattern of incidence, gastroesophageal junctional adenocarcinoma was 
combined with esophageal adenocarcinoma, while gastric adenocarcinoma was 
analyzed separately. 
 
 
4.4 STATISTICAL ANALYSIS  
 
Paper I and IV 
Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs). The exposure was categorized into four levels based on the 
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distribution among the controls, with about an equal number of controls in each 
quartile. The lowest quartile of intake density was set as the reference. Possible 
confounding or effect modification by all established etiologic factors were 
considered in the analyses: age (<55 years, 55-64 years, 65-74 years, or ≥75 years), 
sex, education (≤9 years, 10-12 years, or ≥13 years), BMI (<18.5, 18.5-24.9, 25-29.9, 
or ≥30 kg/m2), tobacco smoking status (never smoker, previous smoker, or current 
smoker of any tobacco), alcohol consumption (no alcohol, >0-15 g/week, 16-70 
g/week, or >70 g/week), physical activity (in quartiles), gastroesophageal reflux 
symptoms (yes or no), and Helicobacter pylori infection (yes or no). A basic model 
included adjustment for age, sex, and energy intake only, while the full multivariate 
model included all variables listed above, selected depending on the specific tumor 
studied.  
 
In paper I, sex-stratified analyses were also performed since the effect of 
estrogen was hypothesized to be sex specific. The variable childbearing was not 
included in the full model for women since non-significant effect was detected. 
Sensitivity analysis was used to identify whether any missing values from those 
food items with extremely high lignan content, i.e. white bread, whole grain 
bread or crisp bread, could influence the association between intake of lignans 
and the studied malignancies. Since there were some missing values in the food 
items, we analyzed the data in two ways: 1) all the missing values were kept as a 
separate category, and 2) exclusion of participants with more than 10% missing 
values. Among these excluded participants, the distributions of missing data were 
similar between different gender and age groups. Since the results were similar 
with or without exclusion, we reported only the results with exclusion.  
 
In paper IV, to derive a dietary pattern defining intake of lignans, quercetin and 
resveratrol, the statistical method RRR was employed using the partial least 
squares procedure in SAS.220 The number of extracted pattern scores equals the 
number of response variables, i.e. three pattern scores were extracted, one for 
each single phytochemical related dietary pattern. The first pattern score was 
retained for the subsequent analyses because it explains most of the variation for 
three phytochemicals intakes. Total intake of all phytochemicals was analyzed in 
energy adjusted densities, i.e., per 1,000 kcal/day. To conduct less population-
dependent pattern variables, the original dietary pattern scores were shortened 
and simplified.221 The simplified pattern scores were obtained by summing 
unweighted standardized scores of intake for each food group, which explains 
most of the inter-individual variation in the original dietary pattern scores. We 
applied the commonly used simplified approach by selecting only food items 
with high factor loadings ≥|0.2|.221 Factor loadings represent the correlations of 
each food item intake with the dietary pattern score. The simplified pattern scores 
were used to evaluate the association between the pattern and the risk of 
esophageal cancer subtypes in logistic regression models. The level of food 
pattern score was categorized into quintiles based on the distribution among the 
control participants. To test for linear trend across dietary pattern scores, we used 
the median scores within each quintile, and treated these values as a continuous 
variable. 
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Paper II  
Lignan values were not normally distributed; therefore the log-transformed values of 
lignan intake and serum ENL were used in the Pearson’s correlation analyses. A total 
of five observations outside the 95% CIs of the corresponding values were excluded, 
leaving 135 participants for final analysis. The following variables were considered as 
potential confounders since they might influence the metabolism of dietary lignans: 
age (categorized into three groups: 55-61, 62-69, or >69 years), BMI (≤24.9, 25-29.9, 
or ≥30 kg/m2), constipation (yes or no), gastrointestinal disease history (yes or no), 
and diabetes (yes or no). The analyses were implemented in both crude and 
multivariable models. The basic model included adjustment for age only, while the 
full multivariable model included all variables listed above. The partial Pearson’s 
correlation was used to calculate the adjusted correlation coefficients in the full 
model. Test of linear trend across BMI categories was conducted by assigning the 
median of BMI in each BMI category and then treating these values as a continuous 
variable in the model. Additional analyses stratified by BMI subgroups were also 
conducted. Analysis of variance (ANOVA) and t-test were used to compare the mean 
values of serum concentration of ENL in the subgroups when appropriate. 
 
 
Paper III 
Hazard ratios (HRs) and 95% CIs were computed using Cox proportional hazard 
models, with follow-up person-days as the underlying time metric.222 Proportional 
hazards assumption was tested for all potential confounders that were included in the 
final model and all variables conformed to the assumption of proportionality. Possible 
confounding or effect modification by the following known risk factors were 
considered in the analyses: age (categorized into three groups: <60, 60-70, or >70 
years), sex, education (≤9, 10-12, or ≥13 years), BMI (<25, 25-29.9, or ≥30 kg/m2), 
tobacco smoking status (never smoking, previous smoking, or current smoking of any 
tobacco), alcohol drinking (quartile of total alcohol intake per week), energy intake 
(quartile of total energy intake per day), gastroesophageal reflux symptoms (yes or 
no), gastric ulcer (yes or no), duodenal ulcer (yes or no), and diabetes (yes or no). 
Sex-stratified analyses were also performed, but we displayed only the results for men 
and women combined, and for men separately since the number of female cases was 
too few to analyze separately.  
 
All P values presented are two-sided and P< 0.05 was considered statistically 
significant.  
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5 RESULTS 
5.1 PAPER I 
 
Study participants 
In total, 618 case patients were recruited; including 189 esophageal adenocarcinoma 
cases (participation rate 88%), 262 gastroesophageal junctional adenocarcinoma cases 
(84%), and 167 esophageal squamous cell carcinoma cases (73%). The number of 
control subjects was 820 (73%). The participants with more than 10% missing values 
of food items were excluded, leaving 181 cases of esophageal adenocarcinoma, 255 
cases of gastroesophageal junctional adenocarcinoma, 158 cases of esophageal 
squamous cell carcinoma, and 806 controls for final analyses (Table 4). The average 
intakes of lignans were 1754.6 µg/day among controls and 1645.4 µg/day among 
cases. 
 
 
Lignans and esophageal or gastroesophageal junctional adenocarcinoma 
Dose-dependent associations were observed between lignan intake and esophageal 
adenocarcinoma, as well for gastroesophageal junctional adenocarcinoma (all p for 
trends <0.05) (Paper 1, Table 2). The adjusted ORs indicated a 35% and a 63% 
reduced risk in the highest lignans exposure quartile compared to the lowest quartile, 
for esophageal adenocarcinoma and gastroesophageal junctional adenocarcinoma, 
respectively. Similar results were found in analyses of men only (Paper 1, Table 3). 
The number of female cases was too low to allow statistically robust estimates, but 
the point ORs were also decreased in women consuming higher levels of lignans. 
When combining the cases of esophageal and gastroesophageal junctional 
adenocarcinoma in the analysis, a stronger dose-dependent decreased risk was found 
with higher intake of lignans (Figure 8). 
 
 
Lignans and esophageal squamous-cell carcinoma 
After adjustment for confounding factors, no clear trend remained in the association 
between dietary lignans and risk of esophageal squamous cell carcinoma (p for 
trend=0.25), although a decreased point OR was indicated in the highest exposed 
quartile compared to the lowest (OR 0.66, 95% CI 0.38-1.15) (Paper 1, Table 2; 
Figure 8).  
 
 
Conclusion: This study indicates that dietary intake of lignans is associated with a 
decreased risk of adenocarcinoma of the esophagus and gastroesophageal junction, 
while no clear association was found for esophageal squamous-cell carcinoma. 
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Table 4. Baseline characteristics of esophageal cancer case and control participants in a Swedish 
population-based case- control study. 
 
Characteristic 
Control 
Number (%) 
Esophageal 
adenocarcinoma 
Number (%) 
Gastroesophageal 
junctional adenocarcinoma 
Number (%) 
Esophageal squamous-
cell carcinoma 
Number (%) 
Gender     
  Male 667 (82.8)      158 (87.3)           216 (84.7)      114 (72.1) 
  Female 139 (17.2) 23 (12.7)      39 (15.3)      44 (27.9) 
Age (years)     
  <55 127 (15.8) 21 (11.5)      52 (20.4)      13 (8.3) 
  55-64 185 (23.0) 38 (20.1)      57 (22.4)      58 (36.7) 
  65-74 317 (39.2) 88 (48.6)      105 (41.2)      62 (29.2) 
  ≥75 177 (22.0) 34 (18.8)      41 (16.0)      25 (15.8) 
Education (years) 
  ≤9 489 (607) 136 (75.1)      166 (65.1)      114 (72.2) 
  10-12 158 (19.6) 22 (12.2)      54 (21.2)      23 (14.6) 
  ≥13 159 (19.7) 23 (12.7)      35 (13.7)      21 (13.2) 
Body mass index (kg/m2)    
  <18.5 9 (1.1) 1 (0.6)      3 (1.2)      5 (3.1) 
  18.5-24.9 553 (69.0) 75 (41.4)      139 (54.5)      102 (64.6) 
  25.0-29.9 215 (26.8) 84 (46.4)      89 (34.9)      41 (26.0) 
  ≥30.0 25 (3.1) 21 (11.6)      24 (9.4)      10 (6.3) 
Tobacco smoking 
  Never 321 (39.8) 55 (30.4)      42 (16.5)      20 (12.6) 
  Ever 309 (38.4) 84 (46.4)      121 (47.5)      42 (26.6) 
  Current 176 (21.8) 42 (23.2)      92 (36.0)      96 (60.8) 
Alcohol consumption (g/week)    
  0 128 (15.9) 35 (19.3)      31 (12.2)      15 (9.5) 
  0-15 214 (26.5) 53 (29.2)      72 (28.2)      32 (20.3) 
  16-70 286 (35.5) 51 (28.2)      77 (30.2)      38 (24.0) 
  >70 178 (22.1) 42 (23.2)      75 (29.4)      73 (46.2) 
Physical activitya     
Ⅰ-low 179 (22.2) 45 (24.9)      53 (20.8)      36 (22.8) 
Ⅱ 256 (31.8) 53 (29.3)      71 (27.8)      55 (34.8) 
Ⅲ 217 (27.0) 42 (23.1)      68 (26.7)      36 (22.8) 
Ⅳ-high 154 (19.0) 41 (22.7)      63 (24.7)      31 (19.6) 
Reflux     
  Yes 131 (16.3) 110 (60.8)     74 (29.0)      25 (15.8) 
  No 675 (83.7) 71 (39.2)     181 (71.0)      133 (84.2) 
Dietary phytoestrogen intake (µg/day)   
 Total lignansb 1754.6 1709.3     1619.2      1607.7 
a Physical activity was measured by a combination of 12 variables, reflecting activities during leisure time and at work. 
b Including secoisolariciresinol, matairesinol, lariciresinol, isolariciresinol, pinoresinol, syringaresinol, and medioresinol. 
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Figure 8. Multivariable-adjusted odds ratios and 95% confidence intervals for 
esophageal cancer in relation to lignan intake in a Swedish nationwide case-control 
study. 
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By sex: 
 
 
                          Women                                                          Men 
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5.2 PAPER II 
Dietary intake of lignans and serum enterolactone 
Among the 135 study participants aged 55-75 years, the average energy-adjusted 
dietary intake of total lignans was 1,616µg/day (standard deviation ±424 µg/day) 
according to the FFQ-87, and 1,516 µg/day (±409 µg/day) for the FFQ-97 (Paper II, 
Table 1). The estimates of dietary lignan intake were different for the two FFQs 
(t=3.2, p=0.002). The mean concentration of serum ENLwas 23.2 nmol/L (±15.4 
nmol/L) (Paper II, Table 2). Approximately 60% of the daily intake of total lignans 
was derived from bread, while fruit and vegetable intake accounted for 25% (Figure 
9).  
 
Correlation between dietary lignans and serum enterolactone 
The Pearson’s correlation coefficients between lignan intake and serum concentration 
of ENL are presented in Paper II, Table 1. Dietary lignans assessed by the FFQ-97 
were statistically significantly correlated with serum ENL in the crude and 
multivariably adjusted models (r=0.16, p=0.06; r=0.22, p=0.01, respectively), as well 
as when converted lignan values were used (r=0.17, p=0.04; r=0.24, p=0.006, 
respectively) (Table 5). However, no such correlation was found for the FFQ-87 with 
lignan intake (r=0.09, p=0.30), nor with converted lignans (r=0.12, p=0.19). The 
correlation between the two FFQs was statistically significant (r=0.59, p<0.0001).   
Pearson’s correlations between intake of total lignans and of converted lignans and 
serum ENL in BMI subgroups are shown in Table 6. The highest correlation was 
observed in obese women (BMI ≥30.0 kg/m2).  
 
 
Conclusion: The present study shows that the validity of FFQ-based estimates of 
dietary lignan intake depends on the number of food items containing lignans in the 
FFQ, and potentially the BMI of the study subjects. 
 
Figure 9. Food sources for major contribution of dietary intake of lignans among 135 
Swedish Women. 
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Table 5. Pearson’s correlation between energy-adjust dietary intake of lignans based on the food frequency questionnaire (FFQ) and serum concentration 
for enterolactone.a 
  Serum vs. FFQ-87b Serum vs. FFQ-97b FFQ-87 vs. FFQ-97 
Intake No. Crude 
(P-value) 
Adjustedc 
(P-value) 
Crude 
(P-value) 
Adjustedc 
(P-value) 
Crude 
(P-value) 
Total lignans 135d 0.06 (0.47) 0.09 (0.30) 0.16 (0.06) 0.22 (0.01) 0.59 (<0.0001) 
Converted lignanse 135d 0.08 (0.33) 0.12 (0.19) 0.17 (0.04) 0.24 (0.006) 0.62 (<0.0001) 
a All dietary intakes of lignans and serum enterolactone were log-transformed. 
b FFQ-87: food frequency questionnaire, 1987 version (45 food items containing lignans); FFQ-97: food frequency questionnaire, 1997 version (65 food items containing lignans). 
c Adjusted for age, body mass index (BMI <25, 25-29.9, ≥30 kg/m2), constipation (yes/no), gastrointestinal disease history (yes/no), and diabetes (yes/no). 
d Five outliers (95% CI) were excluded. 
e Expected amount of dietary lignans was converted to enterolactone in the intestine using conversion factors: matairesinol=0.62, secoisolariciresinol=0.72, lariciresinol=1.01,  
pinoresinol=0.55, syringaresinol=0.44, pinoresinol=0.55, syringaresinol=0.04, medioresinol=0.8. 
 
Table 6. Pearson correlation between energy-adjusted dietary intake of lignans based on the food frequency questionnaire (FFQ) and serum 
concentration of enterolactone stratified by body mass index.a 
BMI (kg/m2)e 
 No. 
         Serum vs. FFQ-87b 
 
Serum vs. FFQ-87_convertedc 
 
Serum vs. FFQ-97b 
 
Serum vs. FFQ-97_Convertedc 
 
Crude  
(P-value) 
Adjustedd 
(P-value) 
Crude 
(P-value) 
Adjustedd 
(P-value) 
Crude  
(P-value) 
Adjustedd 
(P-value) 
Crude 
(P-value) 
Adjustedd 
(P-value) 
1 (<25) 54 0.007 (0.96) -0.005(0.97) 0.04 (0.76) 0.03 (0.85) 0.13 (0.35) 0.14 (0.34) 0.13 (0.35) 0.14 (0.33) 
2 (25.0-29.9) 50 0.11 (0.47) 0.11 (0.48) 0.11 (0.44) 0.12 (0.43) 0.08 (0.57) 0.14 (0.36) 0.08 (0.60) 0.19 (0.23) 
3 (≥30.0) 29 0.13 (0.50) 0.24 (0.26) 0.15 (0.45) 0.27 (0.20) 0.36 (0.06) 0.38 (0.07) 0.37 (0.05) 0.38 (0.07) 
 P-value for trendf  0.15 0.12 0.15 0.13 0.09 0.04 0.12 0.05 
a All dietary intakes of lignans and serum enterolactone were log-transformed. 
b FFQ-87: food frequency questionnaire, 1987 version (45 food items containing lignans); FFQ-97: food frequency questionnaire, 1997 version (65 food items containing lignans). 
c Expected amount of dietary lignans could be converted to enterolactone in the intestine. 
d Adjusted for age, constipation (yes/no), gastrointestinal disease history (yes/no), diabetes (yes/no), when applicable. 
e Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters; two subjects had missing BMI values. 
f Test for trend across BMI categories was conducted by assigning the median of BMI in each BMI category and then treating these values as a continuous variable
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5.3 PAPER III 
Study participants 
The study included 81,670 study participants, including 36,697 women (44.9 %) and 
44,973 men (55.1 %). Sex-specific baseline characteristics of these participants divided 
by quartiles of dietary lignan intake in energy density are shown in Paper III, Table 1. 
Compared with women and men with low intake of lignans, those with higher intake 
were more likely to have a postsecondary education, and have history of diabetes and 
ulcer, and less likely to smoke, drink alcohol and have reflux, while the BMI was 
similar between groups. During an average of 9.9 years of follow-up, 83 cases (69 male 
and 14 female) of esophageal or gastroesophageal junctional adenocarcinoma and 128 
cases (72 male and 56 female) of gastric adenocarcinoma were identified.  
 
Lignan intake and esophageal and gastric adenocarcinoma 
The HRs between higher dietary lignan intake and risk of esophageal or gastric 
adenocarcinoma indicated slight inverse point risk estimates, but no statistically 
significantly decreased risks were identified, and no dose-response trends were 
observed (Figure 10). In the entire cohort (men and women combined), the adjusted 
HR of adenocarcinoma of esophagus or gastroesophageal junction in the highest 
quartile of lignan intake was 0.97 (95% CI: 0.46-2.01) (Paper III, Table 2). The 
corresponding HR for gastric adenocarcinoma was 0.87 (95% CI: 0.51-1.52) (Paper 
III, Table 2). Similar results were observed when only men were analyzed.  
 
 
Conclusion: This study found no clear decreased risk of esophageal or gastric 
adenocarcinoma among persons consumed higher amounts of lignans. A reason for the 
non-significant association in the present cohort study might be the limited number of 
cases. 
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Figure 10. Multivariable-adjusted hazard ratios and 95% confidence interval of 
esophageal and gastric adenocarcinoma in relation to lignan intake. 
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5.4 PAPER IV 
Study participants 
The study included 594 cases of esophageal cancer and 806 controls. Controls had a 
higher intake of tea, lettuce, whole grain bread and mixed vegetables than the case 
groups, but they consumed less milk (t -test, p<0.05). No differences were found for 
intake of tomatoes and wine. Intake of quercetin and lignans were higher among 
controls than in each case group (t -test, p<0.05, data not shown), while intake of 
resveratrol was similar for controls and cases (t-test, p=0.68). The simplified pattern 
scores were positive in the control group, but negative in all three case groups.  
 
 
Food Groups Contributing to the Lignans, Quercetin and Resveratrol Pattern 
Score 
Tea, wine, lettuce, mixed vegetables, tomatoes, milk, and whole grain bread, with a 
factor loading ≥|0.2|, were the most important food items defining level of dietary 
lignans, quercetin, and resveratrol, based on the estimation of the RRR procedure, and 
retained in the simplified food pattern (Table 7). Pearson’s correlation coefficients of 
the food pattern scores with food items were slightly lower for the simplified food 
pattern score compared with the original food pattern. Both the original and simplified 
food pattern scores correlated strongest with tea and wine intake, which explained most 
of the variation in the original food pattern scores. Milk intake was the only item 
negatively associated with the studied pattern scores (Table 7). 
 
 
Dietary Pattern Characterized by Lignans, Quercetin and Resveratrol and Risk of 
Esophageal Cancer by Histologic type 
The identified food pattern characterized by lignans, quercetin and resveratrol was 
strongly associated with risk of esophageal adenocarcinoma, gastroesophageal 
junctional adenocarcinoma, and esophageal squamous-cell carcinoma (Figure 11). 
Dose-dependent associations were found between higher simplified food pattern scores 
and a decreased risk of each of the studied tumors (all p for trend < 0.05). Comparing 
the extreme quintiles (quintile 5 versus quintile 1) of scores in the fully adjusted model 
showed decreased risk estimates of esophageal adenocarcinoma (OR 0.24, 95% CI: 
0.12-0.49), esophageal squamous-cell carcinoma (OR 0.31, 95% CI: 0.15-0.65), and 
gastroesophageal junctional adenocarcinoma (OR 0.49, 95% CI: 0.28-0.84) (Paper IV, 
Table 3). 
 
 
Conclusion: A dietary pattern characterized by high combined intake of lignans, 
quercetin, and resveratrol was strongly associated with a decreased risk of all types of 
studied esophageal cancer in this study. High food pattern scores for these three 
phytochemicals were derived mainly from a high consumption of tea, wine, lettuce, 
mixed vegetables, tomatoes, and whole grain bread, and a low consumption of milk. 
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Table 7. Food groups mainly contributing to a high phytochemicals (lignans, quercetin, 
and resveratrol) food pattern score.  
 
Original food pattern scoreb 
 
Simplified food pattern scorec 
 
Dietary Intakea 
 
Pearson's correlation 
coefficient 
Factor loading 
 
Pearson's correlation coefficient 
 
Tea 0.70 0.48 0.70 
Wine 0.52 0.36 0.71 
Lettuce  0.39 0.27 0.37 
Mixed vegetables 0.34 0.23 0.28 
Tomatoes 0.32 0.22 0.29 
Milk -0.31 -0.21 -0.28 
Whole grain bread 0.29 0.20 0.10 
a. The food intake was expressed in energy-adjust densities as per 1000 kcal/day. 
b. Original food pattern score was estimated by using reduced rank regression analysis. Original food 
pattern score was estimated by using reduced rank regression analysis. 
c. A simplified food pattern score was obtained by summing standardized consumption of tea, wine, 
lettuce, mixed vegetables, tomatoes, milk and whole grain bread intake in energy-adjust densities. 
 
 
 
Figure 11. Multivariable-adjusted odds ratios and 95% confidence intervals for 
esophageal cancer in relation to dietary pattern characterized by intakes of lignans, 
quercetin, and resveratrol. 
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6 DISCUSSION 
 
6.1 METHODOLOGICAL CONSIDERATION 
 
6.1.1 Study design 
Population-based case-control study 
Case-control studies compare persons with the disease (case) with persons without that 
specific disease (control) (Figure 12). The proportions of exposure of interest are then 
compared between case and control groups. Compared to a prospective cohort study, 
the case-control design is relatively inexpensive and requires fewer subjects. This 
design is therefore particularly valuable for studying a rare disease with a long expected 
latency period between the exposure and the disease. This design also has advantages 
for studying associations of a disease with several exposures, which is particularly 
valuable for detecting unknown risk factors for a rare disease, such as esophageal 
cancer. However, a case-control study usually collects data retrospectively, when the 
disease status is already known. This strategy is potentially vulnerable to information 
bias, i.e. recall bias, which might differ between cases and controls. Another major 
pitfall of case-control design is selection bias. A main source of selection bias is the 
inappropriate selection of controls. The selected controls should be similar to the cases 
in all respects other than having the disease in question, or be representative of all 
persons without the disease in the population from which the cases are selected. This 
bias could be largely reduced by using a nationwide population-based design, which 
was used in Paper I and IV. We identified the cases and controls throughout the whole 
Swedish population. This so called “population-based” design reduces the selection 
bias by selecting subjects representing the situation of the whole Swedish population. 
 
 
Validation study 
The FFQ is the most used measurement method to assess dietary nutrient or food 
intake. The interpretation of epidemiologic data based on the FFQ depends on the 
validity of this dietary measurement. Validity refers to the degree to which the 
questionnaire actually measures the aspect of diet that it was designed to measure, and 
it is usually tested by comparing the data based on the questionnaire with those 
measured by a more accurate method, that is, a “gold standard”. Virtually, no truly 
perfect test that can be used as a gold standard exists, since all measurements have 
errors, although these differ in their magnitude. In absence of a perfect test, the best 
available comparison method is usually considered as a gold standard, i.e. the 
application of a biomarker for a specific nutrient intake. A crucial point in the selection 
of a gold standard is that its errors should be independent of the method being 
evaluated. Therefore, the fundamental advantage of using a biomarker is that its 
measurement errors are uncorrelated with errors in the FFQ. 
 
After consumption, plant lignans are converted by the gut microflora into mammalian 
enterolignans, primarily ENL. ENL is widely used as the gold standard biomarker to 
calibrate dietary lignan intake. However, biomarkers have been criticized as an 
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imprecise measurement of diet, since they can be influenced by many factors, such as 
differences in absorption and metabolism, day-to-day variation, and laboratory 
measurement errors. In Paper II, only one single sample was analyzed for serum 
concentration of ENL. Since the biological level is dynamic, fluctuating substantially 
over time, one measurement at a time point may not reflect long-term intake, which the 
questionnaire was designed to evaluate. These errors in total result in weakening any 
association between the biomarker and the questionnaire, even when the dietary 
measurement is precise and accurate. In order to overcome the drawback of using a 
biomarker, we employed several strategies to reduce the extraneous variation in the 
biomarker. Several factors that can influence the metabolism of plant lignans and the 
absorption of mammalian lignans were added into the adjustment, i.e. age, constipation, 
diabetes, and gastrointestinal disease history. Since BMI is indicated as an important 
determinant of the serum ENL concentration, additional analyses stratified by BMI 
subgroups were also conducted. Further criteria should be considered to eliminate the 
random laboratory errors, i.e. by obtaining biological samples at several time points 
with a quantity of samples per subject and having larger sample size. 
 
 
Cohort study 
In a cohort study, the investigator selects a group of exposed individuals (free of 
disease) and a group of non-exposed individuals (free of disease) and follows up both 
groups to compare the occurrence of the outcome under study (Figure 12). It is 
particularly valuable for assessing the effects of rare exposures, and to allow the 
investigation of multiple exposures. Another advantage of a cohort study is that the 
prospective design minimizes the potential for recall and other biases in assessing the 
exposure and has validity of the exposure assessment. Cohort studies often involve 
follow-up of populations over a long period in order to determine whether the 
participants develop the disease of interest. Therefore, such investigations are usually 
time and economy-consuming. Furthermore, loss to follow-up is a major source of bias 
in most cohort studies. If the loss to follow-up is related to both exposure and outcome, 
the incidence rates calculated in the exposed and non-exposed groups will clearly be 
difficult to interpret. Likewise, non-participation and non-response can also introduce 
biases that can complicate the interpretation of the study findings. 
 
In Paper III, the data was prospectively collected from the SMC and the COSM. In 
Sweden, the whole population can be linked to various national registers by using the 
unique personal identity number. The nationwide complete registers, i.e. Cancer 
Register, Patient Register, National Diabetes Register, Emigration Register, Register of 
Total Population, and the Death Register provide valid follow-up of all cohort 
members. 
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Figure 12. Design of cohort and case-control studies. 
 
 
6.1.2 Sources of error 
Two types of error afflict epidemiologic studies: systematic error and random error. 
Systematic error, also termed as bias, occurs in the design, conduct or analysis of a 
study. It is characterized by the nature that repeated measurement or increased study 
size does not help to eliminate this type of error. The nature of this error affects the 
study’s internal validity, and is often classified into selection bias, information bias and 
confounding. On the other hand, random error refers to the degree of precision, and is 
approaching zero as the sample size becomes infinitely large. 
 
 
Systematic error (internal validity) 
 
Selection bias 
Selection bias is present when the association between an exposure and an outcome 
differs between patients in the study and patients not in the study. This systematic error 
often arises in case-control studies since the way in which cases and controls are 
recruited might be related to the exposure. The major selection bias occurring in 
population-based case-control studies might be due to the inappropriate selection of 
controls, when the exposure proportion in recruited controls is not representative of the 
proportion in the source population from which the cases were recruited. Selection bias 
due to non-participation of controls should not have been a major problem in our case-
control studies Paper I and IV, since the controls were randomly chosen from the 
Swedish general population and the overall participation rate in the control group 
(73%) was similar to the case group (82%). The main reason for non-participation 
among controls was due to their unwillingness to be interviewed. In order to classify 
the possibility of the selection bias due to non-participation of controls, a small group 
of 24 controls who refused to participate in the study initially was contacted. They were 
afterward persuaded to be involved in the study. The analysis showed no differences 
between these 24 controls and other control subjects in terms of age, sex, BMI, reflux 
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symptoms, use of tobacco, alcohol, and all studied covariates. This similarity indicates 
that non-participation among controls did not introduce an important selection bias. 
 
Selection bias is less of a problem in a prospective cohort study, since the exposed and 
unexposed subjects are free of disease at the entry of follow-up. However, it ought to 
be kept in mind that a selection bias could be introduced in a prospective design when 
the loss of follow-up is different among exposed and non-exposed groups. The linkage 
to various nationwide registers in Paper III actually provides virtually complete 
follow-up for all participants, and therefore minimizes selection bias.  
 
 
Information bias 
1) Misclassification of exposure 
Some degree of misclassification of lignan intake due to measurement error associated 
with the FFQ was unavoidable. For example, the FFQ might have overestimated a 
number of food groups, particularly lignan intakes from fruit and vegetables,213 and the 
FFQ was not designed specifically for lignan intake, making it difficult to obtain full 
coverage of related food sources. In a prospective study (Paper III), the 
misclassification of lignan measurement tends to be non-differential, that is, similar in 
cases and controls. It might lead to attenuation of possible effects, and this may explain 
the lack of statistically significant associations in that study. Despite this 
misclassification and other unavoidable errors by using the FFQ in a prospective study, 
the validation study (Paper II) indicated that the FFQ was a reasonably useful tool to 
assess dietary intake of lignans.223 On the other hand in the studies with retrospective 
case-control design (Paper I and IV), the systematic error is more likely to be 
differential, whereby the rate of misclassification differs in case and control groups. 
Differential misclassification can result in associations that prove to be wrong. In 
Paper I and IV, the non-blinded professional interviewers conducted the interviews, 
which might introduce information bias differentially. However, all interviewers were 
unaware of the study hypothesis and trained to treat cases and controls in a strictly 
equal way. Recall bias is a common type of differential misclassification that often 
occurs in case-control studies. It is widely recognized that cases might be more 
concerned in recalling their dietary habit and therefore result in more over-reporting of 
true exposure than controls, who may be less likely to recall a true exposure. The net 
effect of the bias is to exaggerate the difference between cases and controls and lead to 
a higher likelihood of detecting statistically significant associations. 
 
In Paper I and IV, the lignan exposure was assessed based on diet 20 years prior to the 
interview, resulting in increased risk of misclassification of the true exposure, but we 
chose this approach to assess dietary habits during a time window when the interaction 
between diet and cancer is possible. This method of assessment of dietary items 20 
years earlier has been validated with good results and showed that such assessment 
captures a combination of previous and current dietary habits.196  
 
2) Misclassification of outcome 
In Paper I and IV, a comprehensive organization for the rapid ascertainment of cases 
was used. In order to reduce misclassification of the tumor site or histologic type, 
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uniform routines for the documentation of tumors of the patients were introduced in all 
participating departments. 
 
In Paper III, all incident cases of esophageal and gastric adenocarcinoma were 
identified through the Swedish National Cancer Register, which was established to be 
63% complete for esophageal adenocarcinoma and 98% complete for gastric 
adenocarcinoma.200,201 Specifically, the validity of using the Swedish National Cancer 
Register to identify esophageal and gastric cancer was excellent, 73% for esophageal 
and gastric adenocarcinoma, and 93% for esophageal squamous cell carcinoma. 
Therefore, the large and validated national register minimized the possibility of under-
ascertainment of cancer cases. Furthermore, in order to avoid detection bias, we 
excluded all participants diagnosed with any cancer during the first year of follow-up. 
 
 
Confounding 
Confounding, which might explain the observed association (or null-association) is due 
to the effect of a third factor that is both a risk factor for the disease and is associated 
with the exposure in question. Failure to account for confounding can result in spurious 
associations. Three criteria must be fulfilled in order to refer to a factor as a 
confounder. First, the factor needs to be associated with the study exposure. Second, 
the factor needs to be associated with risk of the disease of interest. Third, the factor 
should not be the effect of exposure, namely an intermediate step in the causal pathway 
between the exposure and outcome. Confounding is a most important threat to the 
validity of data from observational studies in general. In nutritional epidemiologic 
studies, it is extremely difficult to exclude confounding since intake of various food 
items and nutrients are often strongly correlated. 
 
For example, the main food sources of lignans in the Swedish population are whole 
grain bread, soft bread, and crisp bread, which are also the major sources for cereal 
fiber intake. Therefore, lignan intake is highly correlated with cereal fiber intake. 
Lignans might be a kind of derivative component of cereal fiber and therefore might act 
as an intermediate step in the casual pathway between cereal fiber intake and 
esophageal cancer. Hence, cereal fiber intake was not considered as a confounder for 
the potential association between lignan intake and esophageal cancer in the current 
thesis. 
 
In Paper I and IV, the controls were selected by age and sex matching in order to 
mimic the distribution among cases. This strategy, together with the adjustment for all 
relevant potential confounders for esophageal cancer in the analysis, would minimize 
the confounding effect of these factors. In Paper III, information was missing on some 
important potential confounding factors, including Helicobacter pylori infection, the 
main risk factor of gastric adenocarcinoma, and use of antibiotics, which might reduce 
serum concentrations of ENL.  
 
Random error (precision) 
One of the advantages in Paper I and IV is the relatively large sample size, reducing 
the risk of random error. We included virtually all cases of esophageal and 
gastroesophageal junctional adenocarcinoma in Sweden during a 3-year period. 
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Limitations of Paper II include the small sample size, although it was not smaller than 
that of other phytoestrogen validation studies. Another limitation that could increase the 
risk of random error was that only a single fasting blood sample was used as a gold 
standard. The high intra-individual variation with poor precision when using a single 
measurement might lead to misclassification of the ENL exposure. However, the 
concentration of serum ENL in the study was in line with the concentrations observed 
in other Swedish studies. In Paper III, although the size of total cohort is large, we 
obtained only a limited number of esophageal and gastric adenocarcinoma cases, 
suggesting limited power.  
 
 
6.2 INTERPRETATION AND IMPLICATION 
Lignan intake and risk of esophageal cancer 
Results from Paper I indicate that dietary intake of lignans is associated with a 
decreased risk of adenocarcinoma of the esophagus and gastroesophageal junction, but 
not for esophageal squamous cell carcinoma. The beneficial effects of lignans on 
esophageal and gastroesophageal junctional adenocarcinoma suggested in this study 
might be attributed to their structural similarities to estrogen. The estrogenic effects of 
lignans are widely assumed to be mediated by the mammalian metabolite ENL and via 
activating estrogen receptors (ERs).164 Evidence from previous studies suggest that the 
protective effect of estrogen on esophageal cancer is mediated by the ERs.165 Since the 
presence of ERs has been identified in esophageal tissue,166,224 a linkage between 
mammalian lignans and esophageal cancer via ERs is possible. Isoflavone is another 
type of phytoestrogen that has been found to have an anti-carcinogenic effect. 
However, isoflavones are commonly exhibited in soybeans, which are rare in the 
Western diet. Therefore, we did not include isoflavones in the current study. It is 
important to state that the results identified here are specifically related to a diet rich in 
phytoestrogen lignans, not supplementation with the same compounds and the results 
might be related to other compounds in the same diet acting on their own or in a 
synergistic manner with phytoestrogen lignans.  
 
Although the above case-control study suggested a beneficial effect of lignan intake in 
the development of esophageal cancer, the results from our prospective cohort study 
Paper III found no clear support for this hypothesis. We found inverse point risk 
estimates of esophageal and gastroesophageal junctional adenocarcinoma among those 
with higher dietary lignan intake compared to the lowest category, but they were not 
statistically significant. Although this cohort study did not provide strong evidence for 
any inverse association, the results from these two studies were to some extent 
consistent. A reason for the non-significant results in the present cohort study might be 
ascribed to the limited number of cases. Furthermore, since the misclassification of the 
exposure in a prospective cohort study design tends to be non-differential, i.e. similar in 
cases and non-cases, it might lead to attenuation of possible effects, and this may also 
contribute to the lack of statistically significant associations in the present study. 
Further prospective studies with larger sample size are warranted before we can 
establish the role of lignans in the development of esophageal and gastric 
adenocarcinoma. 
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Validity of FFQ-based assessment for lignan intake    
The results from Paper II show that the validity of FFQ-based estimates of dietary 
lignan intake depends on the number of food items containing lignans in the FFQ, and 
potentially the BMI of the study subjects. 
 
The reasons for the low correlation between lignan intake and serum ENL might be 
diverse. FFQs might overestimate the consumption of a number of food groups, 
particularly lignan intake from fruit and vegetables,213 and the FFQs were not designed 
specifically for lignan intake; thus it was difficult to obtain full coverage of related food 
sources. On the other hand, concentration of ENL might vary substantially over the 
course of a single day, or different seasons. Furthermore, potentially large inter-
individual variation in the metabolism of plant lignans into mammalian ENL cannot be 
ignored.225 Upon ingestion, plant lignans are transformed into their immediate 
precursor END and then ENL by certain gut microflora.121,226 Therefore, lack of certain 
gut microflora can result in different END-to-ENL ratios. Moreover, persons regularly 
consuming certain lignan-rich foods, such as fruit, vegetables and fiber-rich foods have 
more efficient transformation of plant lignans into mammalian ENL.227,228 Smoking and 
high BMI might decrease the serum concentration of ENL, while constipation might 
enhance the production of ENL due to the decrease of intestinal motility.132,229 
 
To improve the assessment of phytoestrogens using FFQs some modifications might be 
warranted. For example, some improvements might be needed to develop a lignan-
specific questionnaire, in which important exposures such as age, education, and BMI 
will also be included. Furthermore, several criteria should be considered when adopting 
a biomarker to calibrate dietary assessment, e.g. by obtaining serum samples at several 
time points and calculating mean values rather than single values. Although hampered 
by low statistical power, it was interesting that obese participants seemed to show a 
higher correlation between the estimate of plant lignan intake and serum concentration 
of ENL. Speculatively, obese people might be more prone to recalling healthy dietary 
habits, such as intake of fruit and vegetables, compared to non-obese people. The 
difference in assessment of dietary lignan intake using the FFQ-97 and the FFQ-87 
might be due to the fact that the FFQ-97 (65 food items containing lignans) evaluated 
more lignan-containing food items than the FFQ-87 (45 food items containing lignans), 
and the fact that some questions in the FFQ-97 were more precise than those in the 
FFQ-87. Participants were asked to report food intake frequency within eight categories 
ranging from ‘never/ seldom’ to ‘4 times/day’ in the FFQ-87, whereas they were asked 
about the precise frequency (open answers, not pre-specified categories) for commonly 
consumed food items, e.g. tea, in the FFQ-97. In fact, there were differences between 
the FFQ-87 and the FFQ-97 in terms of assessment of tea.  
  
In summary, this validation study indicates that the correlation between plant lignan 
intake based on assessment with the FFQ and serum concentration of ENL is limited, 
which can partly depend on varying metabolism of lignans. Therefore, a cautious 
interpretation of FFQ-based results regarding lignan exposure is recommended, and 
direct measurements of serum ENL might be preferred. 
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Dietary patterns and esophageal cancer 
Paper IV demonstrates that a dietary pattern characterized by high intake of lignans, 
quercetin and resveratrol was inversely associated with risk of esophageal cancer, 
including gastroesophageal junctional adenocarcinoma. With increasing food pattern 
scores, intake of tea, wine, lettuce, mixed vegetables, tomatoes, and whole grain bread 
increases intake, while intake of milk decreases intake.  
 
The RRR method used in the present study is a powerful tool in describing overall 
dietary habit and evaluating the potential association with outcome. It integrates the 
characteristics of both a priori and a posteriori approaches by defining a group of food 
variables assumed to be linked to the outcome and explaining variation in interested 
nutrients. The rationale for using this method is the assumption that variation in intake 
of these nutrients might affect the risk for disease outcome. However, the major 
concern of RRR, and other dietary pattern analysis, is that it might be difficult to 
reproduce the results across different study populations. Because of this, we chose the 
simplified food pattern approach by including only the food items making the most 
important contributions to resveratrol, quercetin and lignan intake. Thus, the identified 
simplified food pattern is easily reproducible in other study populations. This novel 
method has been proven informative in examining associations between dietary 
patterns and several disease outcomes.230,231 Nevertheless, it has been a concern that 
simplification might result in loss of relevant information, therefore is difficult to 
predict the variance in nutrients. However, in the present study, the Pearson’s 
correlation coefficient between the original and simplified scores was relatively high 
(0.85), indicating that the loss of information was limited. 
 
In our dietary pattern analysis, tea, with the highest loading factor in the pattern, has 
been indicated as a rich food resource for intake of quercetin and lignans in several 
Western populations.232 Therefore, the fact that tea was a major determinant of the food 
patterns derived in our study is plausible. It ought to be noted that, during the exposure 
period of interest (around 1970s), green tea was basically non-existent on the Swedish 
market. Therefore all tea intake was assumed to be black tea in the current study. 
Recently, an inverse association between high consumption of black tea and risk of 
esophageal cancer has also been observed in an Italian case-control study.233 Evidence 
from animal research has confirmed the potential anti-carcinogenic effect of black tea, 
which was observed to reduce tumor growth.234 Interestingly, this effect was 
synergistically enhanced by the combination with intake of resveratrol.235 Wine, which 
is rich in resveratrol, was another key component in our defined pattern. It is possible 
that resveratrol contributes to the decreased risk of esophageal cancer among wine 
drinkers seen in some studies.43 High intake of fruit and vegetables also contributes to 
the reduction in esophageal cancer. This finding is consistent with the inverse 
association we found between intake of fruit and vegetables and risk of esophageal 
cancer in our earlier study using the same data.56 This food group is a main source of 
these phytochemicals. Particularly, tomatoes and lettuce, the important contributors for 
quercetin intake, were highlighted in our food pattern. Whole grain bread is the most 
important dietary source of lignan intake in the Swedish population,223 and other 
European countries.236 The highest quartile of whole grain bread intake was associated 
with reduced risk of esophageal cancer, and it was also one of the components in an 
identified “healthy” pattern for esophageal adenocarcinoma.64 The healthy dietary 
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pattern was also characterized by low intake of milk. 64 A high energy contribution 
from milk usually associates with low energy intake from fruit and vegetables, which 
often results in low intake of these three phytochemicals, and high milk consumption 
might increase the risk of esophageal cancer.237  
 
Epidemiologic studies addressing lignans, quercetin, and resveratrol separately in 
relation to risk of esophageal cancer are scarce. The estrogenic and anti-obesity 
properties of lignans might contribute to the reduced risk of esophageal cancers found 
in the present study.126 Animal research has found that quercetin can induce 
apoptosis,238 but no epidemiologic studies have addressed the role of quercetin intake in 
the development of esophageal cancer. A strong inverse association between quercetin 
intake and risk of distal gastric cancer has, however, been reported.239 Resveratrol can 
exert anti-carcinogenic effects, modulate lipid and lipoprotein metabolism, and have 
estrogenic properties.240,241 A food pattern characterized by a high combined intake of 
these three phytochemicals might exert an anti-carcinogenic effect based on the 
synergistic effect in suppression of adipogenesis and induction of apoptosis, as 
indicated in animal research.191 
 
In summary, this case-control study indicates that a high dietary intake of lignans, 
quercetin, and resveratrol (represented by a high intake of tea, wine, tomatoes, lettuce, 
mixed vegetables, whole grain bread, and a low intake of milk) could prevent the 
development of esophageal cancer. 
 
 
 
6.3 FUTURE RESEARCH  
 
The results of this thesis give rise to questions that will hopefully be addressed in 
further research. 
 
Future prospective study with a larger sample size 
A protective role of lignan intake in the development of esophageal cancer might exist, 
but more research is required. Due to the potential estrogenic property of lignans and 
the fact that obese hormones distribute differently in men and women, the protective 
effect of lignans has been hypothesized to be female-specific. However, the low female 
incidence of esophageal cancer in our study did not allow robust estimation of the risk 
separately in women. Future research should be addressed with a larger sample size of 
female cases. The lack of association between lignan intake and esophageal cancer 
detected in the prospective study might be mainly due to the limited statistical power. 
Much larger, prospective, and well-designed long-term studies are needed to investigate 
the potential association. 
 
Specific phytoestrogen composition table  
The FFQ is the traditional tool for dietary measurement in nutritional epidemiology. It 
describes the dietary intake trend in a target population. In most cases, participants are 
required to recall or record the habitual food intake frequency, portion size, cooking 
method, and sometimes, the recipe ingredients. The nutrients phytoestrogen are then 
 48 
calculated by multiplying the food intake frequency, portion size and the nutrients 
contents based on appropriate food composition tables for the target population. 
However, a specific food composition table for phytoestrogen is not available for the 
Swedish population. In the current thesis, the phytoestrogen intake was calculated 
based on the published phytoestrogen contents data from different countries. These 
issues together with the existence of numerous factors that could influence the dietary 
measurement, including varying dietary habit over days/months/seasons/years, 
reporting biases, lifestyle confounders, etc., mean all the dietary assessments are 
associated with some extent of measurement error, which might obscure disease-risk 
associations. Therefore, future efforts should have their emphasis on developing a 
specific phytoestrogen composition table for the Swedish population.  
 
Improvement for phytoestrogen intake assessment 
Various statistical techniques have been developed to reduce dietary measurement 
errors and to better estimate the usual food intakes. However, given the fact that the 
measurement error cannot be fully eradicated, true intake is still not really calculated. 
For these reasons, the dietary biomarker enterolactone measured in biological 
specimens, such as serum, plasma, urine, are increasingly being used as an alternative 
instrument for measuring dietary phytoestrogen lignan measurement in modern 
nutritional epidemiology. The rational to use biomarkers is that they are objective 
measurements and are independent of all the biases and errors associated with study 
subjects and dietary measurement methods. However, the level of biomarker 
enterolactone is also influenced by various factors, including bioactivity of microflora, 
interactions between nutrients, genetic backgrounds, gene-gene interactions, laboratory 
measurement errors, BMI, and medication. These important metabolic and genetic 
factors may induce the differences in digestion, absorption, transport, metabolism, 
biotransformation, and excretion of phytoestrogens and finally modulate the correlation 
of phytoestrogens exposure with risk of esophageal cancer. Currently, very little is 
known about the possible gene-phytoestrogens or gene-gene interactions and very few 
studies to date have considered these important factors. It is therefore important for 
nutritional scientists to use biomarkers for phytoestrogen exposure measurement in 
future studies, with consideration of a genetic influence. Moreover, given the existence 
of limitations in both dietary measurements and biomarkers, more advanced statistical 
methods that combine self-reported nutrient intake with relevant nutrient biomarker can 
be applied to strengthen the analysis of phytoestrogen-esophageal cancer hypothesis. 
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7 CONCLUSIONS 
 
 High dietary intake of lignans might decrease the risk of adenocarcinoma of the 
esophagus and gastroesophageal junction. 
 
 The validity of food frequency questionnaire-based estimates of dietary lignan 
intake is limited and might depend on the number of food items containing 
lignans in the food frequency questionnaire, and potentially the body mass 
index of the study subjects. Interpretations made on FFQ-based results 
regarding lignan exposure should be made with cautiousness. 
 
 A dietary pattern with high intake of lignans, quercetin and resveratrol might 
counteract the development of esophageal cancer. 
  
 50 
8 ACKNOWLEDGEMENTS 
 
 
I would like to take the opportunity to express my sincere gratitude to all of you who 
have encouraged and supported me and my PhD study in the Upper Gastrointestinal 
Surgery group. 
 
Especially, my sincere thanks to: 
 
Yunxia Lu, my main supervisor, for introducing me to the interesting field of cancer 
and nutritional epidemiology, for providing me with outstanding training in 
biostatistics, for giving me invaluable advice, for inspiring me, for all the interesting 
discussions, and for challenging me all the time. I am deeply grateful for your never 
failing support. 
 
Jesper Lagergren, my co-supervisor and head of Upper Gastrointestinal Surgery 
group, for your solid and broad knowledge and experience in clinical research, for your 
quick and invaluable comments and suggestions on our manuscripts, for your constant 
encouragement, for your always improving the work environment in our group.  
 
Agneta Yngve, my co-supervisor, for sharing with me your deep knowledge in public 
health nutrition, for your constructive comments on our manuscripts, for your constant 
encouragement for the PhD study and future career. Thank you very much for your 
kind understanding and support. 
 
Alicja Wolk, co-author, from the Institute of Environmental Medicine (IMM), for 
giving me invaluable advice in nutritional epidemiology, for providing me the data 
access into two important cohorts for my research: the Swedish Mammography Cohort 
and the Cohort of Swedish Men. 
 
Herman Adlercreutz, co-author, from the Institute for Preventive Medicine, Nutrition 
and Cancer, Folkhälsan Research Center and Division of Clinical Chemistry, 
Biomedicum, University of Helsinki, for sharing your expertise in phytoestrogens, for 
your detailed advice on our manuscript. 
 
Niclas Håkansson, co-author, data manager and statistician from the Institute of 
Environmental Medicine (IMM), for providing me the dataset and helpful SAS code 
for the analysis. 
 
Jose Luis Peñalvo, co-author, from Department of Epidemiology and Populations 
Genetics, National Center for Cardiovascular Research (CNIC), Madrid, Spain, for 
your kind support and for sharing your technique in laboratory test for serum 
enterolactone. 
 
Yunjian Xu, my mentor, Uppsala University, for sharing your experience and 
providing helpful advice whenever I need. 
 51 
Lizzy Leigh, for sharing your expertise in English editing for all my papers and the 
current thesis. 
 
All present and former colleagues, PhD students in Upper Gastrointestinal Surgery 
group, thank you all so much for creating a welcoming, friendly atmosphere, for 
sharing so much fun together during those after work activities! A special thank you to:  
 
Anna Lindam, PhD student and statistician, we were registered at the same date 
(2010.08.26). Thank you so much for numerous interesting discussions for both the 
research and life, for sharing important information with me, for never giving up 
persuading me to join the coffee break (fika), for bringing me to your home in 
Östersund, for getting me to try horse-riding for the first time in my life, and for 
helping me to improve the methodology of my thesis. Maartje Van Der Schaaf, PhD 
student, for being the pre-opponent for my dissertation. Nele Brusselaers, postdoc, for 
helping me out in the meta-analysis, and for contributing to the thesis’s revision. 
Ulrika Eriksson, Margrete Gellervik, and Karin Vikström, our research 
administrators, for providing me very helpful administrative support. Fredrik 
Mattsson, Asif Mohammed Johar and Jesper Lagergren, for challenging me in Ping 
Pong. Lovisa Backemar, Ylva Hellstadius, Wenjing Tao, Pernilla Lagergren, 
Rickard Ljung, Anna Wikman, Omid Sadr-Azodi, Maryam Derogar, Carl 
Kilander, Lena Martin, Magdalena Plecka Östlund, Tomas Sjöberg Bexelius, for 
all their rewarding discussions, and for creating a stimulating research atmosphere. 
 
My family, my great parents, for your unconditional and endless love, for always 
supporting my decision. My sister Fang Lin, and my brother Xing Lin, for taking care 
very well of me as a little sister, and for encouraging me to go forward with whatever I 
like. My partner Chen, for every single minute. My best friends, Haiyun Chen, Jun 
Chen, Huan Chen, Lun Suo you are the right people I can always talk to. All my 
other dear friends, for being here: Peng Zhang, Ying Yin, Chenge Li, Xiaohu Chen, 
Lingjing Chen, Xiaoying Zhang, Dong Yang, Rui Wang, Alice, Krisna, Matilda, 
Sarah, Malin, Charlotte, and Tong. 
 52 
9 REFERENCES 
 
 
1. Lagergren J, Lagergren P. Oesophageal cancer. BMJ. 2010;341:c6280. 
2. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. 
CA Cancer J Clin. Jul 2013;63(4):232-248. 
3. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol 
Metab. Dec 1998;12(4):605-623. 
4. Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer 
protection. Environ Health Perspect. Oct 1995;103 Suppl 7:103-112. 
5. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, 
and breast cancer risk in Japan. J Natl Cancer Inst. Jun 18 2003;95(12):906-
913. 
6. Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H. 
Serum enterolactone and risk of breast cancer: a case-control study in eastern 
Finland. Cancer Epidemiol Biomarkers Prev. Apr 2001;10(4):339-344. 
7. Hedelin M, Klint A, Chang ET, et al. Dietary phytoestrogen, serum 
enterolactone and risk of prostate cancer: the cancer prostate Sweden study 
(Sweden). Cancer Causes Control. Mar 2006;17(2):169-180. 
8. Strom SS, Yamamura Y, Duphorne CM, et al. Phytoestrogen intake and 
prostate cancer: A case-control study using a new database. Nutrition and 
Cancer-an International Journal. 1999;33(1):20-25. 
9. Johnsen NF, Olsen A, Thomsen BL, et al. Plasma enterolactone and risk of 
colon and rectal cancer in a case-cohort study of Danish men and women. 
Cancer Causes Control. Jan 2010;21(1):153-162. 
10. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of 
isoflavones on human cancer cell lines established from the gastrointestinal 
tract. Cancer Res. Dec 1 1993;53(23):5815-5821. 
11. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and 
mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2010. Available from 
http://globocan.iarc.fr. 
12. Blot WJ, Devesa SS, Fraumeni JF, Jr. Continuing climb in rates of esophageal 
adenocarcinoma: an update. JAMA. Sep 15 1993;270(11):1320. 
13. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. Dec 4 
2003;349(23):2241-2252. 
14. Badar F, Anwar N, Mahmood S. Geographical variation in the epidemiology of 
esophageal cancer in Pakistan. Asian Pac J Cancer Prev. Apr-Jun 
2005;6(2):139-142. 
15. Wu KS, Huo X, Zhu GH. Relationships between esophageal cancer and spatial 
environment factors by using Geographic Information System. Sci Total 
Environ. Apr 15 2008;393(2-3):219-225. 
16. Socialstyrelsen. Statistics from the Cancer Register: National Board of Health 
and Welfare. Accessed on August 24, 2013. 
17. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and 
gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol. 
May 1986;17(5):482-487. 
18. Yang PC, Davis S. Epidemiological characteristics of adenocarcinoma of the 
gastric cardia and distal stomach in the United States, 1973-1982. Int J 
Epidemiol. Jun 1988;17(2):293-297. 
19. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric 
cardia and adjacent sites. Br J Cancer. Sep 1990;62(3):440-443. 
20. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by 
histology, United States, 1998-2003. Int J Cancer. Sep 15 2008;123(6):1422-
1428. 
 53 
21. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United 
States by race, sex, and histologic type, 1977-2005. Br J Cancer. Sep 1 
2009;101(5):855-859. 
22. Lagergren J, Mattsson F. No further increase in the incidence of esophageal 
adenocarcinoma in Sweden. International Journal of Cancer. Jul 15 
2011;129(2):513-516. 
23. Schmassmann A, Oldendorf MG, Gebbers JO. Changing incidence of gastric 
and oesophageal cancer subtypes in central Switzerland between 1982 and 
2007. Eur J Epidemiol. Oct 2009;24(10):603-609. 
24. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and 
mortality in Europe. Int J Cancer. Mar 1 2008;122(5):1118-1129. 
25. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma 
in Norway 1958-1992: incidence time trend variability according to 
morphological subtypes and organ subsites. Int J Cancer. May 2 
1997;71(3):340-344. 
26. Moller H. Incidence of cancer of oesophagus, cardia and stomach in Denmark. 
Eur J Cancer Prev. Feb 1992;1(2):159-164. 
27. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the 
esophagus among white Americans by sex, stage, and age. J Natl Cancer I. Aug 
20 2008;100(16):1184-1187. 
28. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the 
oesophageal adenocarcinoma epidemic. Gut. Jan 8 2013. 
29. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and 
cardia one disease, two, or several? Seminars in Oncology. Aug 
2004;31(4):444-449. 
30. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the 
esophagogastric junction: results of surgical therapy based on 
anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 
Sep 2000;232(3):353-361. 
31. Buas MF, Vaughan TL. Epidemiology and Risk Factors for Gastroesophageal 
Junction Tumors: Understanding the Rising Incidence of This Disease. 
Seminars in Radiation Oncology. Jan 2013;23(1):3-9. 
32. Lagergren J, Mattsson F. Diverging trends in recent population-based survival 
rates in oesophageal and gastric cancer. PLoS One. 2012;7(7):e41352. 
33. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma 
incidence and mortality. Cancer. Mar 15 2013;119(6):1149-1158. 
34. Cen P, Banki F, Cheng L, et al. Changes in age, stage distribution, and survival 
of patients with esophageal adenocarcinoma over three decades in the United 
States. Ann Surg Oncol. May 2012;19(5):1685-1691. 
35. Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the 
esophagus and esophagogastric junction. Recent Results Cancer Res. 
2000;155:1-14. 
36. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the 
problem and who is at risk? Gut. Mar 2005;54 Suppl 1:i1-5. 
37. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. 
Semin Oncol. Aug 2004;31(4):450-464. 
38. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic 
gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New 
Engl J Med. Mar 18 1999;340(11):825-831. 
39. Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's 
oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. 
World J Gastroenterol. Mar 14 2007;13(10):1585-1594. 
40. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet. Mar 7 
2009;373(9666):850-861. 
41. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. 
Incidence of Adenocarcinoma among Patients with Barrett's Esophagus. New 
Engl J Med. Oct 13 2011;365(15):1375-1383. 
42. Chow WH, Blot WJ, Vaughn TL, et al. Body mass index and risk of 
adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer I. Jan 21 
1998;90(2):150-155. 
 54 
43. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of 
smoking, alcohol and body size and risk of adenocarcinomas of the stomach 
and esophagus (United States). Cancer Causes Control. Oct 2001;12(8):721-
732. 
44. Lagergren J, Bergstrom R, Nyren O. Association between body mass and 
adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. Jun 1 
1999;130(11):883-+. 
45. La Vecchia C, Negri E, Lagiou P, Trichopoulos D. Oesophageal 
adenocarcinoma: a paradigm of mechanical carcinogenesis? Int J Cancer. Nov 
20 2002;102(3):269-270. 
46. Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux 
disease in obesity: pathophysiological and therapeutic considerations. Obes Rev. 
Feb 2002;3(1):9-15. 
47. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent 
risk factor for GERD symptoms and erosive esophagitis. American Journal of 
Gastroenterology. Jun 2005;100(6):1243-1250. 
48. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. 
Semin Oncol. Oct 1999;26(5 Suppl 15):2-8. 
49. Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and 
gastric cardia adenocarcinoma: a meta-analysis. Epidemiology. May 
2011;22(3):344-349. 
50. Hashibe M, Boffetta P, Janout V, et al. Esophageal cancer in Central and 
Eastern Europe: Tobacco and alcohol. International Journal of Cancer. Apr 1 
2007;120(7):1518-1522. 
51. Zhang ZF, Kurtz RC, Sun M, et al. Adenocarcinomas of the esophagus and 
gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. 
Cancer Epidemiol Biomarkers Prev. Oct 1996;5(10):761-768. 
52. Tramacere I, Pelucchi C, Bagnardi V, et al. A meta-analysis on alcohol drinking 
and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol. Feb 
2012;23(2):287-297. 
53. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and 
alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. 
International Journal of Cancer. Feb 1 2000;85(3):340-346. 
54. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC. Alcohol 
consumption and the risks of adenocarcinoma and squamous cell carcinoma of 
the esophagus. Gastroenterology. Apr 2009;136(4):1215-1224, e1211-1212. 
55. Navarro Silvera SA, Mayne ST, Risch H, et al. Food group intake and risk of 
subtypes of esophageal and gastric cancer. Int J Cancer. Aug 15 
2008;123(4):852-860. 
56. Terry P, Lagergren J, Hansen H, Wolk A, Nyren O. Fruit and vegetable 
consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer 
Prev. Aug 2001;10(4):365-369. 
57. Cheng KK, Sharp L, McKinney PA, et al. A case-control study of oesophageal 
adenocarcinoma in women: a preventable disease. Br J Cancer. Jul 
2000;83(1):127-132. 
58. Chen H, Tucker KL, Graubard BI, et al. Nutrient intakes and adenocarcinoma 
of the esophagus and distal stomach. Nutr Cancer. 2002;42(1):33-40. 
59. Takezaki T, Gao CM, Wu JZ, et al. Dietary protective and risk factors for 
esophageal and stomach cancers in a low-epidemic area for stomach cancer in 
Jiangsu province, China: Comparison with those in a high-epidemic area. 
Japanese Journal of Cancer Research. Nov 2001;92(11):1157-1165. 
60. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of 
esophageal and gastric cancers. J Natl Cancer Inst. Sep 17 2003;95(18):1404-
1413. 
61. Gonzalez CA, Pera G, Agudo A, et al. Fruit and vegetable intake and the risk of 
stomach and oesophagus adenocarcinoma in the European Prospective 
Investigation into Cancer and Nutrition (EPIC-EURGAST). International 
Journal of Cancer. May 15 2006;118(10):2559-2566. 
62. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: 
role of obesity and diet. J Natl Cancer Inst. Jan 18 1995;87(2):104-109. 
 55 
63. Zhang ZF, Kurtz RC, Yu GP, et al. Adenocarcinomas of the esophagus and 
gastric cardia: the role of diet. Nutr Cancer. 1997;27(3):298-309. 
64. Chen H, Ward MH, Graubard BI, et al. Dietary patterns and adenocarcinoma of 
the esophagus and distal stomach. Am J Clin Nutr. Jan 2002;75(1):137-144. 
65. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of 
esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. Oct 
2001;10(10):1055-1062. 
66. Tzonou A, Lipworth L, Garidou A, et al. Diet and risk of esophageal cancer by 
histologic type in a low-risk population. Int J Cancer. Nov 4 1996;68(3):300-
304. 
67. Mulholland HG, Cantwell MM, Anderson LA, et al. Glycemic index, 
carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's 
esophagus, and esophageal adenocarcinoma. Cancer Causes Control. Apr 
2009;20(3):279-288. 
68. Wu AH, Tseng CC, Hankin J, Bernstein L. Fiber intake and risk of 
adenocarcinomas of the esophagus and stomach. Cancer Causes Control. Sep 
2007;18(7):713-722. 
69. Van Horn L. Fiber, lipids, and coronary heart disease. A statement for 
healthcare professionals from the Nutrition Committee, American Heart 
Association. Circulation. Jun 17 1997;95(12):2701-2704. 
70. Lupton JR, Turner ND. Potential protective mechanisms of wheat bran fiber. 
Am J Med. Jan 25 1999;106(1A):24S-27S. 
71. Marlett JA, McBurney MI, Slavin JL. Position of the American Dietetic 
Association: health implications of dietary fiber. J Am Diet Assoc. Jul 
2002;102(7):993-1000. 
72. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-
oesophageal reflux disease: a cross sectional study in volunteers. Gut. Jan 
2005;54(1):11-17. 
73. Terry P, Lagergren J, Ye WM, Wolk A, Nyren O. Inverse association between 
intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology. Feb 
2001;120(2):387-391. 
74. Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and 
Esophageal adenocarcinoma within the European Prospective Investigation into 
Cancer and Nutrition (EPIC). J Natl Cancer I. Mar 1 2006;98(5):345-354. 
75. O'Doherty MG, Cantwell MM, Murray LJ, Anderson LA, Abnet CC. Dietary 
fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and 
esophageal adenocarcinoma. Int J Cancer. Sep 15 2011;129(6):1493-1502. 
76. Chen KH, Mukaisho KI, Sugihara H, Araki Y, Yamamoto G, Hattori T. High 
animal-fat intake changes the bile-acid composition of bile juice and enhances 
the development of Barrett's esophagus and esophageal adenocarcinoma in a rat 
duodenal-contents reflux model. Cancer Sci. Nov 2007;98(11):1683-1688. 
77. Becker DJ, Sinclair J, Castell DO, Wu WC. A comparison of high and low fat 
meals on postprandial esophageal acid exposure. Am J Gastroenterol. Jul 
1989;84(7):782-786. 
78. Nebel OT, Castell DO. Lower esophageal sphincter pressure changes after food 
ingestion. Gastroenterology. Nov 1972;63(5):778-783. 
79. Bobe G, Peterson JJ, Gridley G, Hyer M, Dwyer JT, Brown LM. Flavonoid 
consumption and esophageal cancer among black and white men in the United 
States. International Journal of Cancer. Sep 1 2009;125(5):1147-1154. 
80. Jiao L, Kramer JR, Rugge M, et al. Dietary intake of vegetables, folate, and 
antioxidants and the risk of Barrett's esophagus. Cancer Causes Control. May 
2013;24(5):1005-1014. 
81. Lagergren J, Nyren O. Do sex hormones play a role in the etiology of 
esophageal adenocarcinoma? A new hypothesis tested in a population-based 
cohort of prostate cancer patients. Cancer Epidem Biomar. Oct 1998;7(10):913-
915. 
82. Lindblad M, Garcia Rodriguez LA, Chandanos E, Lagergren J. Hormone 
replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br 
J Cancer. Jan 16 2006;94(1):136-141. 
 56 
83. Cronin-Fenton DP, Murray LJ, Whiteman DC, et al. Reproductive and sex 
hormonal factors and oesophageal and gastric junction adenocarcinoma: a 
pooled analysis. Eur J Cancer. Jul 2010;46(11):2067-2076. 
84. Lagergren J, Jansson C. Sex hormones and oesophageal adenocarcinoma: 
influence of childbearing? Br J Cancer. Oct 17 2005;93(8):859-861. 
85. Lu Y, Lagergren J. Reproductive factors and risk of oesophageal cancer, a 
population-based nested case-control study in Sweden. Br J Cancer. Jul 24 
2012;107(3):564-569. 
86. Green J, Roddam A, Pirie K, Kirichek O, Reeves G, Beral V. Reproductive 
factors and risk of oesophageal and gastric cancer in the Million Women Study 
cohort. Br J Cancer. Jan 3 2012;106(1):210-216. 
87. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in 
oesophageal adenocarcinoma. Int J Cancer. Dec 1 2002;102(4):422-427. 
88. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic 
variations in the rising incidence of esophageal adenocarcinoma in white males. 
Cancer. Aug 1 2001;92(3):549-555. 
89. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric 
atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus 
and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. Mar 3 
2004;96(5):388-396. 
90. Tobacco smoking. IARC Monogr Eval Carcinog Risk Chem Hum. 1986;38:35-
394. 
91. Alcohol drinking. IARC Working Group, Lyon, 13-20 October 1987. IARC 
Monogr Eval Carcinog Risks Hum. 1988;44:1-378. 
92. Haas SL, Ye W, Lohr JM. Alcohol consumption and digestive tract cancer. 
Curr Opin Clin Nutr Metab Care. Sep 2012;15(5):457-467. 
93. Berretta M, Lleshi A, Fisichella R, et al. The role of nutrition in the 
development of esophageal cancer: what do we know? Front Biosci (Elite Ed). 
2012;4:351-357. 
94. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and 
socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. 
J Natl Cancer Inst. Sep 3 1997;89(17):1277-1284. 
95. Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a meta-
analysis. Ann Oncol. Feb 2013;24(2):301-308. 
96. Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Risk factors for 
esophageal cancer and the multiple occurrence of carcinoma in the upper 
aerodigestive tract. Surgery. Jan 2002;131(1 Suppl):S1-6. 
97. Cheng KK, Day NE. Nutrition and esophageal cancer. Cancer Causes Control. 
Jan 1996;7(1):33-40. 
98. Liu J, Wang J, Leng Y, Lv C. Intake of fruit and vegetables and risk of 
esophageal squamous cell carcinoma: A meta-analysis of observational studies. 
Int J Cancer. Jul 15 2013;133(2):473-485. 
99. Lu SH, Camus AM, Tomatis L, Bartsch H. Mutagenicity of extracts of pickled 
vegetables collected in Linhsien County, a high-incidence area for esophageal 
cancer in Northern China. J Natl Cancer Inst. Jan 1981;66(1):33-36. 
100. Li JY, Ershow AG, Chen ZJ, et al. A case-control study of cancer of the 
esophagus and gastric cardia in Linxian. Int J Cancer. May 15 1989;43(5):755-
761. 
101. Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-
temperature beverages and foods and esophageal cancer risk--a systematic 
review. Int J Cancer. Aug 1 2009;125(3):491-524. 
102. Yuan JM. Green tea and prevention of esophageal and lung cancers. Mol Nutr 
Food Res. Jun 2011;55(6):886-904. 
103. Wang Z, Tang L, Sun G, et al. Etiological study of esophageal squamous cell 
carcinoma in an endemic region: a population-based case control study in 
Huaian, China. Bmc Cancer. 2006;6:287. 
104. Chen YK, Lee CH, Wu IC, et al. Food intake and the occurrence of squamous 
cell carcinoma in different sections of the esophagus in Taiwanese men. 
Nutrition. Jul-Aug 2009;25(7-8):753-761. 
 57 
105. Tobey NA, Sikka D, Marten E, Caymaz-Bor C, Hosseini SS, Orlando RC. 
Effect of heat stress on rabbit esophageal epithelium. Am J Physiol. Jun 
1999;276(6 Pt 1):G1322-1330. 
106. Meijssen MA, Tilanus HW, van Blankenstein M, Hop WC, Ong GL. Achalasia 
complicated by oesophageal squamous cell carcinoma: a prospective study in 
195 patients. Gut. Feb 1992;33(2):155-158. 
107. Sandler RS, Nyren O, Ekbom A, Eisen GM, Yuen J, Josefsson S. The risk of 
esophageal cancer in patients with achalasia. A population-based study. JAMA. 
Nov 1 1995;274(17):1359-1362. 
108. Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer 
risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 
Oct 2010;105(10):2144-2149. 
109. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phyto-oestrogens: 
Where are we now? Brit J Nutr. May 1998;79(5):393-406. 
110. Setchell KDR. Soy isoflavones - Benefits and risks from nature's selective 
estrogen receptor modulators (SERMs). Journal of the American College of 
Nutrition. Oct 2001;20(5):354s-362s. 
111. Vanharanta M, Voutilainen S, Lakka TA, van der Lee M, Adlercreutz H, 
Salonen JT. Risk of acute coronary events according to serum concentrations of 
enterolactone: a prospective population-based case-control study. Lancet. Dec 
18-25 1999;354(9196):2112-2115. 
112. Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis 
of the effect of soy protein supplementation on serum lipids. Am J Cardiol. Sep 
1 2006;98(5):633-640. 
113. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, 
and breast cancer risk in Japan. J Natl Cancer I. Jun 18 2003;95(12):906-913. 
114. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent 
risk of breast cancer among Chinese women. Cancer Epidem Biomar. May 
2001;10(5):483-488. 
115. Hedelin M, Klint A, Chang ET, et al. Dietary phytoestrogen, serum 
enterolactone and risk of prostate cancer: the Cancer Prostate Sweden Study 
(Sweden). Cancer Cause Control. Mar 2006;17(2):169-180. 
116. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 
Apr 1997;29(2):95-120. 
117. Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab. 
Dec 1998;12(4):729-742. 
118. Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen 
content of foods consumed in Canada, including isoflavones, lignans, and 
coumestan. Nutr Cancer. 2006;54(2):184-201. 
119. Nurmi T, Heinonen S, Mazur W, Deyama T, Nishibe S, Adlercreutz H. Lignans 
in selected wines. Food Chem. Nov 2003;83(2):303-309. 
120. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H. Lignan 
and isoflavonoid concentrations in tea and coffee. Br J Nutr. Jan 1998;79(1):37-
45. 
121. Borriello SP, Setchell KD, Axelson M, Lawson AM. Production and 
metabolism of lignans by the human faecal flora. J Appl Bacteriol. Jan 
1985;58(1):37-43. 
122. Axelson M, Sjovall J, Gustafsson BE, Setchell KD. Origin of lignans in 
mammals and identification of a precursor from plants. Nature. Aug 12 
1982;298(5875):659-660. 
123. Kilkkinen A, Valsta LM, Virtamo J, Stumpf K, Adlercreutz H, Pietinen P. 
Intake of lignans is associated with serum enterolactone concentration in 
Finnish men and women. J Nutr. Jun 2003;133(6):1830-1833. 
124. Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: 
new precursors of mammalian lignans enterolactone and enterodiol. J Agric 
Food Chem. Jul 2001;49(7):3178-3186. 
125. Owen RW, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H. 
Identification of lignans as major components in the phenolic fraction of olive 
oil. Clinical Chemistry. Jul 2000;46(7):976-988. 
 58 
126. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci. 2007;44(5-
6):483-525. 
127. Stitch SR, Toumba JK, Groen MB, et al. Excretion, isolation and structure of a 
new phenolic constituent of female urine. Nature. Oct 23 1980;287(5784):738-
740. 
128. Nesbitt PD, Lam Y, Thompson LU. Human metabolism of mammalian lignan 
precursors in raw and processed flaxseed. Am J Clin Nutr. Mar 1999;69(3):549-
555. 
129. Rowland IR, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA. 
Interindividual variation in metabolism of soy isoflavones and lignans: 
Influence of habitual diet on equol production by the gut microflora. Nutrition 
and Cancer-an International Journal. 2000;36(1):27-32. 
130. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H. 
Determinants of serum enterolactone concentration. American Journal of 
Clinical Nutrition. Jun 2001;73(6):1094-1100. 
131. Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by 
the gut microflora: a study in germ-free and human flora associated rats. Food 
Chem Toxicol. May 2003;41(5):631-636. 
132. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H. 
Determinants of serum enterolactone concentration. Am J Clin Nutr. Jun 
2001;73(6):1094-1100. 
133. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. 
Bioavailability of phyto-oestrogens. Brit J Nutr. Jun 2003;89:S45-S58. 
134. Setchell KDR, Cole SJ. Method of defining equol-producer status and its 
frequency among vegetarians. J Nutr. Aug 2006;136(8):2188-2193. 
135. Nielsen ILF, Williamson G. Review of the factors affecting bioavailability of 
soy isoflavones in humans. Nutrition and Cancer-an International Journal. 
2007;57(1):1-10. 
136. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H. Lignan 
and isoflavonoid concentrations in tea and coffee. Brit J Nutr. Jan 
1998;79(1):37-45. 
137. Thompson LU, Robb P, Serraino M, Cheung F. Mammalian Lignan Production 
from Various Foods. Nutrition and Cancer-an International Journal. 
1991;16(1):43-52. 
138. Reinli K, Block G. Phytoestrogen content of foods - A compendium of 
literature values. Nutrition and Cancer-an International Journal. 
1996;26(2):123-148. 
139. Pillow PC, Duphorne CM, Chang S, et al. Development of a database for 
assessing dietary phytoestrogen intake. Nutrition and Cancer-an International 
Journal. 1999;33(1):3-19. 
140. Blair RM, Appt SE, Franke AA, Clarkson TB. Treatment with antibiotics 
reduces plasma equol concentration in cynomolgus monkeys (Macaca 
fascicularis). J Nutr. Jul 2003;133(7):2262-2267. 
141. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: A review. Mol Cell 
Endocrinol. May 25 2009;304(1-2):30-42. 
142. Whitten PL, Russell E, Naftolin F. Influence of phytoestrogen diets on estradiol 
action in the rat uterus. Steroids. Jul 1994;59(7):443-449. 
143. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. 
Annu Rev Physiol. 2001;63:165-192. 
144. Welshons WV, Murphy CS, Koch R, Calaf G, Jordan VC. Stimulation of breast 
cancer cells in vitro by the environmental estrogen enterolactone and the 
phytoestrogen equol. Breast Cancer Res Treat. Nov 1987;10(2):169-175. 
145. Mousavi Y, Adlercreutz H. Enterolactone and Estradiol Inhibit Each Others 
Proliferative Effect on Mcf-7 Breast-Cancer Cells in Culture. J Steroid 
Biochem. Mar 1992;41(3-8):615-619. 
146. Sathyamoorthy N, Wang TTY, Phang JM. Stimulation of Ps2 Expression by 
Diet-Derived Compounds. Cancer Research. Feb 15 1994;54(4):957-961. 
147. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by 
mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol 
Biol. Feb 1993;44(2):147-153. 
 59 
148. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids 
inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol. 
Aug 1994;50(3-4):205-212. 
149. Saarinen NM, Huovinen R, Warri A, et al. Enterolactone inhibits the growth of 
7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol 
Cancer Ther. Aug 2002;1(10):869-876. 
150. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the 
activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 
cells. J Steroid Biochem Mol Biol. Apr 2005;94(5):461-467. 
151. Adlercreutz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, 
including lignans and phytoestrogens, on enterohepatic circulation and liver 
metabolism of estrogens and on sex hormone binding globulin (SHBG). J 
Steroid Biochem. 1987;27(4-6):1135-1144. 
152. Adlercreutz H, Hamalainen E, Gorbach SL, Goldin BR, Woods MN, Dwyer JT. 
Diet and plasma androgens in postmenopausal vegetarian and omnivorous 
women and postmenopausal women with breast cancer. Am J Clin Nutr. Mar 
1989;49(3):433-442. 
153. Adlercreutz H, Mousavi Y, Clark J, et al. Dietary phytoestrogens and cancer: in 
vitro and in vivo studies. J Steroid Biochem Mol Biol. Mar 1992;41(3-8):331-
337. 
154. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of 
the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan 
metabolites enterodiol and enterolactone. Mol Cell Biochem. Dec 1999;202(1-
2):91-100. 
155. Pool-Zobel BL, Adlercreutz H, Glei M, et al. Isoflavonoids and lignans have 
different potentials to modulate oxidative genetic damage in human colon cells. 
Carcinogenesis. Jun 2000;21(6):1247-1252. 
156. Prasad K. Antioxidant Activity of Secoisolariciresinol Diglucoside-derived 
Metabolites, Secoisolariciresinol, Enterodiol, and Enterolactone. Int J Angiol. 
Oct 2000;9(4):220-225. 
157. Fukumitsu S, Aida K, Ueno N, Ozawa S, Takahashi Y, Kobori M. Flaxseed 
lignan attenuates high-fat diet-induced fat accumulation and induces 
adiponectin expression in mice. Br J Nutr. Sep 2008;100(3):669-676. 
158. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits 
apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-
dependent, prostaglandin-E2-mediated transactivation of the epidermal growth 
factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. Sep 
2006;147(9):4505-4516. 
159. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin 
receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell 
proliferation. Mol Cell Endocrinol. Mar 26 2008;285(1-2):43-50. 
160. Ekman S, Bergqvist M, Heldin CH, Lennartsson J. Activation of growth factor 
receptors in esophageal cancer--implications for therapy. Oncologist. Oct 
2007;12(10):1165-1177. 
161. Rickard SE, Yuan YV, Thompson LU. Plasma insulin-like growth factor I 
levels in rats are reduced by dietary supplementation of flaxseed or its lignan 
secoisolariciresinol diglycoside. Cancer Lett. Dec 8 2000;161(1):47-55. 
162. Chen LH, Fang J, Sun ZJ, et al. Enterolactone Inhibits Insulin-Like Growth 
Factor-1 Receptor Signaling in Human Prostatic Carcinoma PC-3 Cells. J Nutr. 
Apr 2009;139(4):653-659. 
163. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and 
decreases extracellular vascular endothelial growth factor in human breast 
cancer xenografts. Cancer Lett. Nov 8 2002;185(1):31-37. 
164. Penttinen P, Jaehrling J, Damdimopoulos AE, et al. Diet-derived polyphenol 
metabolite enterolactone is a tissue-specific estrogen receptor activator. 
Endocrinology. Oct 2007;148(10):4875-4886. 
165. Utsumi Y, Nakamura T, Nagasue N, Kubota H, Harada T, Morikawa S. Effect 
of 17 beta-estradiol on the growth of an estrogen receptor-positive human 
esophageal carcinoma cell line. Cancer. May 1 1991;67(9):2284-2289. 
 60 
166. Tiffin N, Suvarna SK, Trudgill NJ, Riley SA. Sex hormone receptor 
immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma. 
Histopathology. Jan 2003;42(1):95-96. 
167. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of 
human estrogen receptor beta isoforms. Biochem Biophys Res Commun. Jun 9 
1998;247(1):75-78. 
168. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin 
receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell 
proliferation. Mol Cell Endocrinol. Mar 26 2008;285(1-2):43-50. 
169. Adlercreutz H. Does fiber-rich food containing animal lignan precursors protect 
against both colon and breast cancer? An extension of the "fiber hypothesis". 
Gastroenterology. 1984;86(4):761-764. 
170. Sung MK, Lautens M, Thompson LU. Mammalian lignans inhibit the growth of 
estrogen-independent human colon tumor cells. Anticancer Research. May-Jun 
1998;18(3A):1405-1408. 
171. Jenab M, Thompson LU. The influence of flaxseed and lignans on colon 
carcinogenesis and beta-glucuronidase activity. Carcinogenesis. Jun 
1996;17(6):1343-1348. 
172. Mutanen M, Pajari AM, Oikarinen SI. Beef induces and rye bran prevents the 
formation of intestinal polyps in Apc(Min) mice: relation to beta-catenin and 
PKC isozymes. Carcinogenesis. Jun 2000;21(6):1167-1173. 
173. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A, Harper P. Dietary 
phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr. 
Dec 2006;136(12):3046-3053. 
174. Zamora-Ros R, Not C, Guino E, et al. Association between habitual dietary 
flavonoid and lignan intake and colorectal cancer in a Spanish case-control 
study (the Bellvitge Colorectal Cancer Study). Cancer Cause Control. Mar 
2013;24(3):549-557. 
175. Ward HA, Kuhnle GGC, Mulligan AA, Lentjes MAH, Luben RN, Khaw KT. 
Breast, colorectal, and prostate cancer risk in the European Prospective 
Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen 
intake derived from an improved database. American Journal of Clinical 
Nutrition. Feb 2010;91(2):440-448. 
176. Ward H, Chapelais G, Kuhnle GGC, Luben R, Khaw KT, Bingham S. Lack of 
prospective associations between plasma and urinary phytoestrogens and risk of 
prostate or colorectal cancer in the European prospective into Cancer-Norfolk 
study. Cancer Epidem Biomar. Oct 2008;17(10):2891-2894. 
177. Kuijsten A, Hollman PC, Boshuizen HC, et al. Plasma enterolignan 
concentrations and colorectal cancer risk in a nested case-control study. Am J 
Epidemiol. Mar 15 2008;167(6):734-742. 
178. Zamora-Ros R, Agudo A, Lujan-Barroso L, et al. Dietary flavonoid and lignan 
intake and gastric adenocarcinoma risk in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study. American Journal of 
Clinical Nutrition. Dec 2012;96(6):1398-1408. 
179. Perez-Vizcaino F, Duarte J, Andriantsitohaina R. Endothelial function and 
cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic 
Res. Oct 2006;40(10):1054-1065. 
180. Kuppusamy UR, Das NP. Potentiation of beta-adrenoceptor agonist-mediated 
lipolysis by quercetin and fisetin in isolated rat adipocytes. Biochemical 
pharmacology. Feb 9 1994;47(3):521-529. 
181. Hsu CL, Yen GC. Induction of cell apoptosis in 3T3-L1 pre-adipocytes by 
flavonoids is associated with their antioxidant activity. Molecular Nutrition & 
Food Research. Nov 2006;50(11):1072-1079. 
182. Schlachterman A, Valle F, Wall KM, et al. Combined Resveratrol, Quercetin, 
and Catechin Treatment Reduces Breast Tumor Growth in a Nude Mouse 
Model. Transl Oncol. Mar 2008;1(1):19-27. 
183. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a 
comprehensive review of human clinical trials. Mol Nutr Food Res. Aug 
2011;55(8):1129-1141. 
 61 
184. Chung MI, Teng CM, Cheng KL, Ko FN, Lin CN. An Antiplatelet Principle of 
Veratrum-Formosanum. Planta Med. Jun 1992;58(3):274-276. 
185. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR, Kim Y. Inhibitory effects of 
resveratrol analogs on unopsonized zymosan-induced oxygen radical 
production. Biochem Pharmacol. Mar 15 1999;57(6):705-712. 
186. Jang MS, Cai EN, Udeani GO, et al. Cancer chemopreventive activity of 
resveratrol, a natural product derived from grapes. Science. Jan 10 
1997;275(5297):218-220. 
187. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of 
stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on 
lipid metabolism. Chem Pharm Bull (Tokyo). May 1982;30(5):1766-1770. 
188. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white 
adipocytes by repressing PPAR-gamma. Nature. Jun 17 2004;429(6993):771-
776. 
189. Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, et al. Resveratrol inhibits 
the growth and induces the apoptosis of both normal and leukemic 
hematopoietic cells. Carcinogenesis. Aug 2002;23(8):1327-1333. 
190. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially 
anticarcinogenic flavonoids and their determinants in adults in The Netherlands. 
Nutrition and cancer. 1993;20(1):21-29. 
191. Park HJ, Yang JY, Ambati S, et al. Combined effects of genistein, quercetin, 
and resveratrol in human and 3T3-L1 adipocytes. Journal of medicinal food. 
Dec 2008;11(4):773-783. 
192. Jansson C, Johansson ALV, Nyren O, Lagergren J. Socioeconomic factors and 
risk of esophageal adenocarcinoma: A nationwide Swedish case-control study. 
Cancer Epidem Biomar. Jul 2005;14(7):1754-1761. 
193. Lagergren J, Jansson C. Sex hormones and oesophageal adenocarcinoma: 
influence of childbearing? Brit J Cancer. Oct 17 2005;93(8):859-861. 
194. Ye WM, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric 
atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the 
esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer I. Mar 3 
2004;96(5):388-396. 
195. Wolk A, Bergstrom R, Hunter D, et al. A prospective study of association of 
monounsaturated fat and other types of fat with risk of breast cancer. Archives 
of Internal Medicine. Jan 12 1998;158(1):41-45. 
196. Wolk A, Bergstrom R, Hansson LE, Nyren O. Reliability of retrospective 
information on diet 20 years ago and consistency of independent measurements 
of remote adolescent diet. Nutr Cancer. 1997;29(3):234-241. 
197. Bahmanyar S, Ye W. Dietary patterns and risk of squamous-cell carcinoma and 
adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a 
population-based case-control study in Sweden. Nutr Cancer. 2006;54(2):171-
178. 
198. Valsta LM, Kilkkinen A, Mazur W, et al. Phyto-oestrogen database of foods 
and average intake in Finland. Br J Nutr. Jun 2003;89 Suppl 1:S31-38. 
199. Mazur WM, Duke JA, Wahala K, Rasku S, Adlercreutz H. Isoflavonoids and 
lignans in legumes: Nutritional and health aspects in humans. J Nutr Biochem. 
Apr 1998;9(4):193-200. 
200. Mazur W, Fotsis T, Wahala K, Ojala S, Salakka A, Adlercreutz H. Isotope 
dilution gas chromatographic-mass spectrometric method for the determination 
of isoflavonoids, coumestrol, and lignans in food samples. Anal Biochem. Jan 
15 1996;233(2):169-180. 
201. Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC. Lignan contents 
of Dutch plant foods: a database including lariciresinol, pinoresinol, 
secoisolariciresinol and matairesinol. Br J Nutr. Mar 2005;93(3):393-402. 
202. Mazur W, Adlercreutz H. Overview of naturally occurring endocrine-active 
substances in the human diet in relation to human health. Nutrition. Jul-Aug 
2000;16(7-8):654-658. 
203. Hertog MGL, Hollman PCH, Vandeputte B. Content of Potentially 
Anticarcinogenic Flavonoids of Tea Infusions, Wines, and Fruit Juices. J Agr 
Food Chem. Aug 1993;41(8):1242-1246. 
 62 
204. Hertog MGL, Hollman PCH, Katan MB. Content of Potentially 
Anticarcinogenic Flavonoids of 28 Vegetables and 9 Fruits Commonly 
Consumed in the Netherlands. J Agr Food Chem. Dec 1992;40(12):2379-2383. 
205. Hertog MGL, Hollman PCH, Katan MB, Kromhout D. Intake of Potentially 
Anticarcinogenic Flavonoids and Their Determinants in Adults in the 
Netherlands. Nutrition and Cancer-an International Journal. 1993;20(1):21-29. 
206. Stecher G, Huck CW, Popp M, Bonn GK. Determination of flavonoids and 
stilbenes in red wine and related biological products by HPLC and HPLC-ESI-
MS-MS. Fresen J Anal Chem. Sep 2001;371(1):73-80. 
207. Lamuelaraventos RM, Romeroperez AI, Waterhouse AL, Delatorreboronat 
MC. Direct Hplc Analysis of Cis-Resveratrol and Trans-Resveratrol and Piceid 
Isomers in Spanish Red Vitis-Vinifera Wines. J Agr Food Chem. Feb 
1995;43(2):281-283. 
208. Lamikanra O, Grimm CC, Rodin JB, Inyang ID. Hydroxylated stilbenes in 
selected American wines. J Agr Food Chem. Apr 1996;44(4):1111-1115. 
209. Jandera P, Skerikova V, Rehova L, et al. RP-HPLC analysis of phenolic 
compounds and flavonoids in beverages and plant extracts using a CoulArray 
detector. J Sep Sci. Jun 2005;28(9-10):1005-1022. 
210. Swedish National Food Administration. Available: 
http://www.slv.se/engdefault.asp 2002. 
211. Willet W. Nutritional epidemiology. 2nd ed. New York: Oxford University 
Press; 1998. 
212. Becher W, Peason M. Riksmaten 1997-1998. Metod och resultatanalys. 
Livesmedelsverket, Upplasa, Sweden, 2002. 
213. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic 
analyses. Am J Epidemiol. Jul 1986;124(1):17-27. 
214. Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: 
New precursors of mammalian lignans enterolactone and enterodiol. J Agr 
Food Chem. Jul 2001;49(7):3178-3186. 
215. Wang GJ, Lapcik O, Hampl R, et al. Time-resolved fluoroimmunoassay of 
plasma daidzein and genistein. Steroids. Jun 2000;65(6):339-348. 
216. Adlercreutz H, Wang GJ, Lapcik O, et al. Time-resolved fluoroimmunoassay 
for plasma enterolactone. Anal Biochem. Dec 15 1998;265(2):208-215. 
217. Stumpf K, Uehara M, Nurmi T, Adlercreutz H. Changes in the time-resolved 
fluoroimmunoassay of plasma enterolactone. Anal Biochem. Aug 15 
2000;284(1):153-157. 
218. Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. 
Evaluating gastric cancer misclassification: a potential explanation for the rise 
in cardia cancer incidence. J Natl Cancer Inst. May 5 1999;91(9):786-790. 
219. Lindblad M, Ye WM, Lindgren AS, Lagergren J. Disparities in the 
classification of esophageal and cardia adenocarcinomas and their influence on 
reported incidence rates. Annals of Surgery. Apr 2006;243(4):479-485. 
220. Hoffmann K, Schulze MB, Schienkiewitz A, Nothlings U, Boeing H. 
Application of a new statistical method to derive dietary patterns in nutritional 
epidemiology. Am J Epidemiol. May 15 2004;159(10):935-944. 
221. Schulze MB, Hoffmann K, Kroke A, Boeing H. An approach to construct 
simplified measures of dietary patterns from exploratory factor analysis. Brit J 
Nutr. Mar 2003;89(3):409-418. 
222. Cox DR, Oakes D. Analysis of survival data. London (U.K.): Chapman and 
Hall;. 1984. 
223. Lin Y, Wolk A, Hakansson N, et al. Validation of FFQ-based assessment of 
dietary lignans compared with serum enterolactone in Swedish women. Br J 
Nutr. May 28 2013;109(10):1873-1880. 
224. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of 
human estrogen receptor beta isoforms. Biochem Bioph Res Co. Jun 9 
1998;247(1):75-78. 
225. Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. 
Interindividual variation in metabolism of soy isoflavones and lignans: 
influence of habitual diet on equol production by the gut microflora. Nutr 
Cancer. 2000;36(1):27-32. 
 63 
226. Setchell KD, Lawson AM, Borriello SP, et al. Lignan formation in man--
microbial involvement and possible roles in relation to cancer. Lancet. Jul 4 
1981;2(8236):4-7. 
227. Nurmi T, Mursu J, Penalvo JL, Poulsen HE, Voutilainen S. Dietary intake and 
urinary excretion of lignans in Finnish men. Br J Nutr. Mar 2010;103(5):677-
685. 
228. Hutchins AM, Lampe JW, Martini MC, Campbell DR, Slavin JL. Vegetables, 
Fruits, and Legumes - Effect on Urinary Isoflavonoid Phytoestrogen and Lignan 
Excretion. Journal of the American Dietetic Association. Jul 1995;95(7):769-
774. 
229. Johnsen NF, Hausner H, Olsen A, et al. Intake of whole grains and vegetables 
determines the plasma enterolactone concentration of Danish women. J Nutr. 
Oct 2004;134(10):2691-2697. 
230. Heidemann C, Hoffmann K, Spranger J, et al. A dietary pattern protective 
against type 2 diabetes in the European Prospective Investigation into Cancer 
and Nutrition (EPIC) - Potsdam Study cohort. Diabetologia. Jun 
2005;48(6):1126-1134. 
231. Nothlings U, Murphy SP, Wilkens LR, et al. A food pattern that is predictive of 
flavonol intake and risk of pancreatic cancer. American Journal of Clinical 
Nutrition. Dec 1 2008;88(6):1653-1662. 
232. Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutr 
Cancer. 2008;60(4):442-449. 
233. Tavani A, Bertuzzi M, Talamini R, et al. Coffee and tea intake and risk of oral, 
pharyngeal and esophageal cancer. Oral Oncol. Oct 2003;39(7):695-700. 
234. Yang CS, Lee MJ, Chen LS, Yang GY. Polyphenols as inhibitors of 
carcinogenesis. Environ Health Persp. Jun 1997;105:971-976. 
235. George J, Singh M, Srivastava AK, et al. Resveratrol and black tea polyphenol 
combination synergistically suppress mouse skin tumors growth by inhibition of 
activated MAPKs and p53. PLoS One. 2011;6(8):e23395. 
236. Tetens I, Turrini A, Tapanainen H, et al. Dietary intake and main sources of 
plant lignans in five European countries. Food Nutr Res. 2013;57. 
237. Bosetti C, La Vecchia C, Talamini R, et al. Food groups and risk of squamous 
cell esophageal cancer in northern Italy. Int J Cancer. Jul 15 2000;87(2):289-
294. 
238. Chen SS, Corteling R, Stevanato L, Sinden J. Polyphenols inhibit indoleamine 
3,5-dioxygenase-1 enzymatic activity--a role of immunomodulation in 
chemoprevention. Discov Med. Nov 2012;14(78):327-333. 
239. Ekstrom AM, Serafini M, Nyren O, Wolk A, Bosetti C, Bellocco R. Dietary 
quercetin intake and risk of gastric cancer: results from a population-based 
study in Sweden. Ann Oncol. Feb 2011;22(2):438-443. 
240. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, 
open questions and promises. J Nutr Biochem. Aug 2005;16(8):449-466. 
241. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. 
Antioxid Redox Sign. Dec 2001;3(6):1041-1064. 
 
 
